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Multi-Omics Integration Through Single-Cell Copy Number Analysis In Cancer
Abstract
Genetic and epigenetic alterations combine to drive cancer progression. Heterogeneous cell populations
within tumors are associated with poor prognosis and outcomes. Copy number aberrations (CNAs), a
genetic variant commonly occurring in tumors, are used as markers to detect subclones and reconstruct
tumor phylogeny. Multi-omics integration between CNAs and other modalities on tumor subclones
facilitates studying the interplay between genome and epigenome, and their effects on transcriptome. So
far, there is still a lack of computational methods for the multi-omics integration of different types of
single-cell and ST tumor sequencing data. Therefore, the aim of this thesis is to extract (allele-specific)
CNA signals in single-cell and ST tumor sequencing data, which enables the integration of multi-omics at
the subclone level. We achieved this through the development of two methods — Alleloscope (Chapter 2)
and Clonalscope (Chapter 3). Alleloscope is a computational method for profiling allele-specific CNAs in
single-cell DNA- and/or transposase-accessible chromatin-sequencing (scDNA-seq, ATAC-seq) data,
enabling integrative analysis of allele-specific copy number and chromatin accessibility. On scDNA-seq
data from gastric, colorectal and breast cancer samples, with validation using matched linked-read
sequencing, Alleloscope finds pervasive occurrence of highly complex, multiallelic CNAs, in which cells
that carry varying allelic configurations adding to the same total copy number coevolve within a tumor. On
scATAC-seq from two basal cell carcinoma samples and a gastric cancer cell line, Alleloscope detected
multiallelic copy number events and copy-neutral loss-of-heterozygosity, enabling dissection of the
contributions of chromosomal instability and chromatin remodeling to tumor evolution. To detect
genetically different subclones based on CNAs, we also developed Clonalscope, a subclone detection
method for different single-cell and ST tumor sequencing data, which leverages prior information from
matched bulk DNA-seq data. Clonalscope implements a nested Chinese Restaurant Process to model the
evolutionary process in tumors. On scRNA-seq and scATAC-seq data from three gastrointestinal tumor
samples, Clonalscope successfully labeled malignant cells and identified genetically different subclones,
which were validated in detail using matched scDNA-seq data. On ST data from a basal cell carcinoma
and two invasive ductal carcinoma samples, Clonalscope was able to label malignant spots, trace
subclones between related datasets, and identify spatially segregated subclones expressing genes
associated with drug resistance and survival.
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ABSTRACT

MULTI-OMICS INTEGRATION THROUGH SINGLE-CELL COPY NUMBER ANALYSIS IN
CANCER
Chi-Yun Wu
Nancy R. Zhang
Genetic and epigenetic alterations combine to drive cancer progression. Heterogeneous cell
populations within tumors are associated with poor prognosis and outcomes. Copy number
aberrations (CNAs), a genetic variant commonly occurring in tumors, are used as markers to detect
subclones and reconstruct tumor phylogeny. Multi-omics integration between CNAs and other
modalities on tumor subclones facilitates studying the interplay between genome and epigenome,
and their effects on transcriptome. So far, there is still a lack of computational methods for the multiomics integration of different types of single-cell and ST tumor sequencing data. Therefore, the aim
of this thesis is to extract (allele-specific) CNA signals in single-cell and ST tumor sequencing data,
which enables the integration of multi-omics at the subclone level. We achieved this through the
development of two methods — Alleloscope (Chapter 2) and Clonalscope (Chapter 3).
Alleloscope is a computational method for profiling allele-specific CNAs in single-cell DNA- and/or
transposase-accessible chromatin-sequencing (scDNA-seq, ATAC-seq) data, enabling integrative
analysis of allele-specific copy number and chromatin accessibility. On scDNA-seq data from
gastric, colorectal and breast cancer samples, with validation using matched linked-read
sequencing, Alleloscope finds pervasive occurrence of highly complex, multiallelic CNAs, in which
cells that carry varying allelic configurations adding to the same total copy number coevolve within
a tumor. On scATAC-seq from two basal cell carcinoma samples and a gastric cancer cell line,
Alleloscope detected multiallelic copy number events and copy-neutral loss-of-heterozygosity,
enabling dissection of the contributions of chromosomal instability and chromatin remodeling to
tumor evolution.
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To detect genetically different subclones based on CNAs, we also developed Clonalscope, a
subclone detection method for different single-cell and ST tumor sequencing data, which leverages
prior information from matched bulk DNA-seq data. Clonalscope implements a nested Chinese
Restaurant Process to model the evolutionary process in tumors. On scRNA-seq and scATAC-seq
data from three gastrointestinal tumor samples, Clonalscope successfully labeled malignant cells
and identified genetically different subclones, which were validated in detail using matched scDNAseq data. On ST data from a basal cell carcinoma and two invasive ductal carcinoma samples,
Clonalscope was able to label malignant spots, trace subclones between related datasets, and
identify spatially segregated subclones expressing genes associated with drug resistance and
survival.
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1. CHAPTER 1 INTRODUCTION
Cancer is a disease caused by intra-tissue evolutionary selection and adaptation. Within cancerous
tissue, genetic mutations and epigenetic modifications combine to shape the transcriptional
program of tumor cells [1, 2]. The three modalities together produce a diverse population within
tumors, from which the subclones with advantageous alterations proliferate and, eventually,
metastasize [3]. These heterogeneous subclones can also be a reservoir for drug resistance and
relapse [4, 5]. Therefore, characterization of subclones differing in any of the modalities and
reconstruction of their evolutionary history are the main focuses of cancer studies.
Since somatic copy number aberrations (CNAs), one type of genetic variants, commonly occur in
cancer, they can be used as makers to identify genetically different subclones. Additionally, CNAs
usually occur in chronological order, so they can also be used to reconstruct tumor phylogenetic
history for the identified subclones. On the other hand, recent advancements in single-cell
technologies enable studying intratumor heterogeneity. With different types of single-cell
technologies, cell populations with distinct profiles of genome, transcriptome, and epigenome can
be characterized within tumors.
As single-cell sequencing technologies evolved, the development of computational methods is also
required to extract important information from the single-cell sequencing data. So far, there have
been a large number of computational tools developed to address technical issues for single-cell
sequencing data of a single modality, and to estimate the real biological signals that might be
missed in the data [6-9]. However, to understand the interplay between different omics, there is still
a lack of method to integrate different modalities for single-cell sequencing data. In this dissertation,
I will focus on two methods we developed – Alleloscope and Clonalscope – for CNA and subclone
detection in scDNA-seq, scRNA-seq, scATAC-seq and ST sequencing data in cancers. The two
methods also allow integrative analysis of different omics on single-cell sequencing data. The
terminologies mentioned above will be reviewed in more detail in the following sections.
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Intratumor heterogeneity
Intratumor heterogeneity is considered to contribute to poor prognosis and outcomes since cancer
cell populations may have distinct characteristics and varying sensitivity to the treatment [10].
Heterogeneous populations in tumors can be distinguished from any difference in their profiles of
genomics, DNA methylation, chromatin accessibility, gene expression, and etc. In the following
paragraphs, common alterations of different modalities will be reviewed.
Within a tumor sample, the difference in cell-specific genomic profiles results from DNA mutations.
DNA mutations are changes in DNA sequences that can be carried after a cell proliferates including
commonly observed single nucleotide variants (SNVs), insertion or deletion (Indel), and CNAs. An
SNV is a single nucleotide alteration in DNA sequences. SNVs can be divided into three main
categories — synonymous, nonsynonymous, and nonsense — depending on if the sequence of
the encoded protein product is changed or not due to an SNV. Indels are usually defined as the
insertions or deletions of DNA sequences less than 1kb into the genomic DNA [11]. During
translation, a transcript is read in sets of three bases, with each set coding for a particular amino
acid. Indels are likely to lead to a frameshift, which changes the reading frame of the sequence
during translation and generates dysfunctional proteins. A translocation is a break in one
chromosome, followed by a fusion to another chromosome. Translocations were shown to influence
the spatial organization of the impacted chromosomes and change the transcriptomic profile [12].
CNAs such as duplications or deletions change the number of copies of a DNA segment. Since
CNAs are the main focuses of this dissertation, they will be introduced in more detail in another
section.
Unlike genetic mutations, epigenetic changes do not change DNA sequences and are usually
reversible. This characteristic enables epigenetic changes regulate cells’ dynamic response to the
environment. A few epigenetic features have been characterized in previous studies such as DNA
methylation and histone modification [13, 14]. DNA methylation is a chemical process during which
a methyl group is added to the cytosine ring in the DNA molecule [15]. DNA methylation was shown
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to regulate chromatin organization and gene expression [16]. Hypermethylation in cancer was
shown to silence the expression of tumor suppressor genes and influence related biological
processes [17]. On the other hand, global hypomethylation was observed in several cancers and
considered to lead to oncogenesis especially when oncogenes are activated [18]. Histone is a
family of proteins that support the structure of a chromosome. It is known that modification of
histones will change chromatin structures [19] and affect downstream gene expression [20].
Both genetic and epigenetic alterations can influence transcriptomic profiles of tumor cells through
changing chromatin accessibility. Chromatin accessibility is the degree how accessible chromatin
is depending on the interactions between DNA and structural proteins that constitute chromatin
[21]. Regions of accessible chromatin allow physical interactions with chromatin-binding factors.
Regulatory elements such as promoters, enhancers and silencers are DNA sequences that
regulate gene expression. For a gene to express properly, these DNA sequences need to be
accessible to specific regulatory proteins [22-24]. In addition to changing the constitution of proteins,
SNVs located at regulatory elements can also impact chromatin accessibility and change
downstream gene expression. The level of DNA methylation was also shown to be anti-correlated
with chromatin accessibility at regulatory elements in cancers [25-27]. The evidence indicates that
different modalities interact with each other and together shape heterogeneity in tumors.

(Allele-specific) copy number aberrations in tumors
Somatic copy number aberrations (CNAs) frequently occur in cancer genomes [28-31], through
which we have derived much of our current understanding of the relationship between genome
instability and tumor evolution [32]. In the diploid human genome, some regions on one or both of
the two homologous chromosomes may be affected by a CNA. Currently, the definition of the size
of CNAs is vague from 50 bp [33] to several Mb [34], but it is usually defined as ≥ 1kb compared
to a reference genome [35-37]. Generally, CNAs can be broadly categorized into different types
including amplifications, deletions, and copy-neutral loss of heterozygosity (CNN-LOH).
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Amplifications can be defined as changes of the genetic materials that increase the total copies of
the normal diploid genome. Similarly, deletions can be defined as changes of the genetic materials
that decrease the total copies of the normal diploid genome. Commonly, when one of the two
homologous regions on the genome is lost, the rest one is duplicated to ensure the total two copies
do not change for the regions [38, 39]. It is also possible that one of the homologous regions is first
duplicated followed by deletion of the same regions on the other chromosome. Even if no change
in the total copies is observed in the regions after the dual events, all the heterozygous single
nucleotide polymorphisms (SNPs) spanning the regions become homozygous. This type of CNAs
with no change in total copies is called CNN-LOH. Notably, LOH events are also observed for
regions with amplifications and deletions [40].
CNAs may or may not have functional effects on tumor cells. When amplifications or deletions
happen in the chromosomal regions encoding genes, expression of the genes is usually increased
or decreased respectively [41]. If the affected genes are oncogenes or tumor suppressor genes,
these CNAs were shown to be highly associated with tumor development and progression [42, 43].
When CNAs are located in the non-coding regions of the genome, they may not lead to change in
any specific gene expression. However, previous studies showed the effects of CNAs are complex.
CNAs not only change the expression of the genes located in the same chromosomal regions, but
also affect the genome-wide gene expression [44]. On the other hand, CNN-LOH events do not
change the total copies of the chromosomal regions. Nevertheless, LOH can result in loss of the
wild-type allele in individuals carrying a germline mutation in tumor-associated genes such as
BRCA1 in breast and ovarian cancer [45]. Loss of wild-type alleles can influence the normal
functions of genes which can lead to profound effects in the whole transcriptome [46].
Accurate detection and profiling of CNAs facilitate cancer prognosis and effective treatment [32].
Tons of studies have analyzed CNAs based on the total copies in different types of tumors using
microarrays or whole-genome sequencing (WGS) data [35-37]. Profiling the recently discovered
LOH events requires analysis of allele-specific CNAs. Allele-specific CNA analysis can be achieved
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by considering change of both total copies and allelic ratios in the same sample. By performing
allele-specific CNA analysis on SNP arrays and bulk DNA sequencing data, previous studies have
identified copy-neutral loss-of-heterozygosity (LOH) events and other allele-specific CNV events
that could lead to dysregulation of oncogenes or tumor suppressor genes in different cancer types
[39, 47-49].

Single-cell and spatial transcriptomic sequencing technologies
Single-cell sequencing technologies enable profiling sequence information in individual cells by
optimizing next-generation sequencing (NGS) [50]. Compared to traditional bulk sequencing
technologies which sequence average information of groups of cells, single-cell sequencing can
reveal the heterogeneity within cell populations [51]. Applications of earlier single-cell technologies
were limited due to the high cost. As the technologies advanced recently, different single-cell
sequencing technologies profiling different omics have been broadly applied in various fields
including developmental biology and cancer biology [50, 52, 53]. The following sections review
some single-cell technologies which will be mentioned later including scRNA-seq, scDNA-seq,
scATAC-seq and spatial transcriptomic sequencing. Their applications in biology will also be briefly
reviewed.
Single-cell RNA sequencing (scRNA-seq) is the most broadly used single-cell sequencing
technology which quantifies the number of different transcripts within individual cells. ScRNA-seq
has the most rapid growth in the scale and robustness of protocols [54]. These protocols differ in
their ways of tagging transcripts and generating libraries. They can be broadly categorized into 1.
Low-throughput plate-based methods and 2. High-throughput droplet-based methods. The Smartseq2 and CEL-Seq2 are two commonly used plate-based methods which are able to sequence
transcripts in full length but with much lower throughputs. Among the more popular droplet-based
methods, 10x Chromium is the most broadly used one, which sequences 3’ or 5’ end of the
transcripts for tens of thousands of cells. With the help of scRNA-seq, substantial studies and the
Human Cell Atlas (HCA) has started to build a more comprehensive reference map of every cell
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type in the human body [53]. By annotating the cell type of each cell, cell type-specific gene
expression can be quantified and compared between different scenarios.
Single-cell DNA sequencing (scDNA-seq), another type of single-cell sequencing technology, is
used to sequence DNA molecules of individual cells. ScDNA-seq is especially useful in the cancer
biology field since it facilitates uncovering tumor heterogeneity by detecting genetic variants in
tumor cells [55]. While single-cell SNV detection requires higher sequencing depth, the current
depth is sufficient for multiplex single-cell copy number profiling in hundreds of thousands of cells
[56, 57]. Most scDNA-seq technologies are accessible to only some sophisticated labs. The 10x
Genomics tried to commercialize the technology in 2018, but unfortunately, the company
discontinues the sale of the product at the end of 2020. Other companies such as TaKaRa Bio also
commercialized technologies to help with library preparation for scDNA-seq. Applications of
scDNA-seq have helped reveal tumor evolutionary history in different cancer types [58, 59].
Recently, several methods have been developed to profile chromatin accessibility at the single-cell
level. For example, Cusanovich et al. applied the strategy of combinatorial indexing to measure
chromatin accessibility in thousands of cells [60]. Another approach, single-cell transposaseaccessible chromatin sequencing (scATAC-seq) originally integrated the bulk ATAC-seq into a
microfluidic platform to map the accessible genome of individual cells [61]. The latest scATAC-seq
is performed on droplet-based platforms, which enables profiling of chromatin accessibility in
hundreds of thousands of cells [62, 63]. ScATAC-seq was applied to profile chromatin accessibility
of cells in the tumor microenvironment [63]. By integrating scRNA-seq and scATAC-seq data, the
association between transcription factors and gene expression can also be studied in tumors [64].
While single-cell sequencing technologies enable the discovery of novel cell types and cell states,
most of these techniques cannot preserve spatial information in tissues. The recently developed
spatial transcriptomic (ST) techniques can profile the entire transcriptome. Here, the NGS-based
ST techniques (versus the image-based methods) will be reviewed [65] .
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The NGS-based approaches encode spatial information before sequencing. 10X Genomics Visium,
one of the popular NGS-based methods, can sequence 55 𝜇𝑚 spots and more than 10,000
transcripts per spot. Visium captures mRNAs on the microarray slide with spatial barcodes before
reverse transcription, so each transcript can be mapped to its original site using the spatial barcode.
Another example of an NGS-based approach is Slide-seq, which captures mRNAs using beads
with random barcodes on the slides [66]. It uses in situ indexing to retrieve the position of each
random barcode. Slide-seq can sequence 10 𝜇𝑚 spots and 500 transcripts per bead [67]. These
ST techniques have been applied in different fields including cancer [68] and development [69] to
study the spatial distribution of different cell types and the cell-cell interactions in tissues.

Multi-omics integration
Integration of multi-omics information on single-cell sequencing data facilitates understanding
complex biological mechanisms. Multi-omics information can be different combinations of single
modalities such as genome, epigenome, transcriptome, proteome, and spatial location in the tissue
microenvironment. Multi-omics data for single cells can be mainly retrieved in two ways [70] – 1.
Simultaneous measurement of multiple types of data within a single cell through the improvement
of technologies or 2. Extraction of information encoded in the sequence in addition to the original
modality.
Most single-cell technologies initially focus on profiling one type of modalities such as scRNA-seq
for gene expression, scATAC-seq for chromatin accessibility, and scDNA-seq for DNA-level
information. Recently, an increasing amount of single-cell technologies have been developed to
measure multiple types of molecules within single cells. For example, CITE-seq [71] and REAPseq [72] can profile whole transcriptome and a set of selected proteins simultaneously. They can
be used to study the relationships between RNA and proteins. Two other examples are the SHAREseq [73] and the 10X Genomics Single Cell Multiome technology, which can simultaneously profile
chromatin accessibility and gene expression within a single cell. These two technologies are
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extremely useful in studying the associations between the binding of transcription factors and gene
expression at the single-cell level.
In addition to technology improvement, existing data can also be re-analyzed to extract signals of
another modality. Specifically, the sequence information in different types of single-cell sequencing
data also encoded signals from DNA-level variants no matter what modality the technology was
originally designed for. For example, SNVs and CNAs, two common types of genomic variants in
tumor cells, were also extracted in scRNA-seq data in previous studies [74, 75] . The genomic
variants can be used to identify genetically different subclones and to reconstruct tumor phylogeny.
By profiling both transcriptome and genomic information in scRNA-seq data, gene expression can
be analyzed at the subclone level. Similarly, DNA-level variants can also be extracted in scATACseq data, so that interplays between genomic variants and chromatin accessibility can be studied
[76]. More details about CNA detection in different types of single-cell sequencing data are
reviewed in the next section.

Copy number detection in single-cell and spatial tumor sequencing data
Copy number detection in single-cell and spatial tumor sequencing data relies on the development
of both technologies and computational methods. ScDNA-seq is the technology used to profile
intratumor DNA-level heterogeneity. Several methods have been applied/developed to detect
coverage-only CNAs in scDNA-seq data. These methods can be categorized based on 1. if Single
or multiple samples are simultaneously analyzed; 2. Diploidy assumption or not; 3. Requirement of
diploid cell for normalization or not; and 4. If they are parametric or non-parametric [7]. For example,
HMMcopy [77], Ginkgo [78] and SCNV [79] are three methods applied to a single sample.
HMMcopy, an HMM-based method originally developed for array CGH data, has been applied to
detect CNAs for scDNA-seq data in multiple studies before other scDNA-seq specific methods such
as Ginko and SCNV came out. Some methods developed later tried to consider multiple samples
at once to pool the signals shared in multiple cells for CNA detection such as SCOPE [80] and
SCICoNE [81]. So far, only two methods have been developed for profiling allele-specific CNAs in
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scDNA-seq data including Alleloscope [76] and CHISEL [82]. The two methods considered multiple
nearby alleles together to compute change in allelic ratios, and discovered much higher intratumor
heterogeneity in scDNA-seq data from different tumor types.
While scDNA-seq is currently the method of choice for profiling intratumor DNA-level heterogeneity,
many published and ongoing cancer sequencing studies opt for the use of other types of single cell
assays, such as scRNA-seq and scATAC-seq. Most cancer studies using scRNA-seq and scATACseq estimate total copy number by smoothing the read coverage, normalized by some appropriately
chosen reference, across each chromosome for each cell [63, 83]. A few methods have been
developed for CNA detection in scRNA-seq data such as inferCNV [75], CopyKAT [84], CaSpER
[85], HoneyBADGER [86], and CONICS [87]. InferCNV and CopyKAT segment the genome and
detect subclones based on coverage changes without using information from matched DNA-seq
data. These two methods were applied to scRNA-seq data of multiple platforms. CaSpER and
HoneyBADGER consider both coverage changes and allelic ratios, but they were mainly developed
for full-length scRNA-seq data. CONICS profiles CNAs in scRNA-seq data with segments from
matched bulk DNA-seq, but it was mainly developed for the full-length scRNA-seq data and does
not infer intratumor subclones.
ST sequencing not only quantifies gene expression for each spot but also provides spatial
coordinates for each spot. Therefore, similar strategies can also be applied to detect CNAs in ST
data like those used for scRNA-seq data. Currently, STARCH is the only CNA inference method
developed particularly for ST data, which leverages the signals from nearby spots to overcome the
sparsity [88]. Another study instead applied inferCNV, which was originally developed for scRNAseq data, to analyze CNA in tumor ST data [89]. Comparatively, fewer methods have been
developed to profile CNAs in scATAC-seq data. To analyze CNAs in scATAC-seq data, a few
studies performed preliminary smoothing and normalization to visualize potential CNA signals
using in-house scripts [63, 64]. Alleloscope can be applied to not only scDNA-seq data, but also
scATAC-seq data jointly with matched bulk DNA-seq data for CNA detection [76].
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2. CHAPTER 2 INTEGRATIVE SINGLE-CELL ANALYSIS OF ALLELE-SPECIFIC
COPY NUMBER ALTERATIONS AND CHROMATIN ACCESSIBILITY IN CANCER
Introduction
Cancer is a disease caused by genetic alterations and epigenetic modifications which, in
combination, shape the dysregulated transcriptional programming of tumor cells [1, 2]. These
somatic genomic events lead to a diverse cellular population from which clones with advantageous
alterations proliferate and metastasize [3]. Comprehensive study of cancer requires the integrative
profiling of genetic and epigenetic changes at single-cell resolution. We consider here the analysis
of two such genomic dimensions – DNA copy number and chromatin accessibility – through
massively parallel single-cell sequencing assays.
First, consider copy number aberrations (CNAs), through which we have derived much of our
current understanding of the relationship between genome instability and tumor evolution [32]. Total
copy number profiling, which estimates the sum of the copy numbers of the two homologous
chromosomes, is inadequate to characterize some types of cancer genomic aberrations. Such
events include the pervasive copy-neutral losses of heterozygosity (LOH) [39, 47-49] and the
intriguing “mirrored events” [90, 91], where cells carrying amplification of one haplotype are
intermingled with cells carrying amplification of the other haplotype. Although the importance of
allele-specific copy number profiling has been emphasized in bulk DNA sequencing analysis [39,
47-49, 92], most single-cell studies profile only total copy number due to the difficulty of reliable
allele-specific estimation at low per-cell coverage [56-59, 78, 93-95]. Recently, Zaccaria and
Raphael developed CHISEL [91], a method for single-cell allele-specific copy number analysis that
relies on externally phased haplotypes. This was the first time that allele-specific of CNAs were
reported at single-cell resolution, but the requirements for high sequencing depth and external
phasing limit the general applicability of CHISEL. Thus, the prevalence of mirrored subclones and
the allelic complexity of CNA regions at single-cell resolution remain largely unexplored.
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Now consider the profiling of chromatin accessibility [61, 96] in the study of epigenetic plasticity of
cancer cells [27, 63, 64, 97, 98]. Because copy number alterations involve large gains and losses
of chromatin, we expect a region’s accessibility to be confounded by changes in its underlying copy
number. Current single cell transposase-accessible chromatin sequencing (scATAC-seq) analyses
estimate the total copy number profile of each cell by smoothing the read coverage across large
bins, normalizing to a control cell population [63, 64]. Yet, the appropriate control is difficult to
identify, as chromatin remodeling can lead to broad shifts in coverage that are unrelated to
underlying copy number. There is yet no reliable method for total or allele-specific copy number
profiling in scATAC-seq data, and thus, CNA and chromatin accessibility are confounded in current
analysis pipelines.
Addressing these challenges, we present Alleloscope, a method for allele-specific copy number
estimation and multiomic profiling in single cells. Alleloscope can be applied to low coverage
scDNA-seq data or to scATAC-seq data with sample-matched bulk DNA sequencing data, and
does not require external haplotype phasing. To investigate the allelic complexity of CNAs in cancer
at single-cell resolution, we first apply Alleloscope to scDNA-seq data from four gastric cancer
samples, four colorectal cancer samples, and two different regions of a breast cancer sample [91,
93, 99]. For five of the gastrointestinal cancer samples, results are validated by 10x linked-read
sequencing which provides accurate phasing information [100-102]. In these datasets, Alleloscope
finds pervasive occurrence of mirrored subclones and other highly complex multi-allelic CNA loci
where cells carrying distinct allelic configurations adding to the same total copy number co-evolve
within a tumor. The ubiquity of such events in all three cancer types analyzed reveals that they may
be a general source of intratumor genetic heterogeneity. We then turn to scATAC-seq data from
two basal cell carcinoma samples with paired bulk whole exome sequencing data [63] and a
complex polyclonal gastric cancer cell line that we also analyzed by scDNA-seq. In these samples,
we evaluate the accuracy of Alleloscope in genotyping and subclone assignment for scATAC-seq
data and demonstrate its application to the integrative analysis of CNA and chromatin accessibility.

11

Results

Overview of Alleloscope model and algorithm
We first describe allele-specific copy number estimation (Fig. 1). Integration with scATAC-seq peak
signals will be described later. Consider the two parental haplotypes, we call the one with higher
count across cells the “major haplotype”, and the other the “minor haplotype”. Note that, within any
single cell, it is possible for the major haplotype to have fewer copies than the minor haplotype. For
each cell 𝑖 and genome region 𝑟, we define two key parameters: (1) the major haplotype proportion
(𝜃𝑖𝑟 ) is the copy number of the major haplotype divided by the total copy number and (2) the total
copy fold change (𝜌𝑖𝑟 ) is the ratio of the total copy number relative to that in normal cells.
Alleloscope starts by segmenting the genome into regions of homogeneous population-average
allele-specific copy number using the bulk coverage and variant allele frequency (VAF) profiles,
derived from pooling reads across cells (Methods). For scATAC-seq data, we recommend that the
segmentation be performed on matched bulk or single-cell DNA-seq data, which ensures that the
characterized CNA regions are supported by evidence from DNA.
An expectation-maximization (EM) algorithm is then applied separately for each region 𝑟 to phase
the SNPs in the region and estimate its major haplotype proportion (𝜃𝑖𝑟 ) for each cell (Fig. 1, Step
3). For each SNP 𝑗 in region 𝑟, let 𝐼𝑗 ∈ {0,1} be the indicator of whether the reference allele of 𝑗 is
(0)
carried by the major haplotype, see example in Fig. 1. An initial estimate 𝐼̂𝑗 is first derived from
(𝑡)
the bulk VAF profile. Then, in iteration 𝑡 of EM, Alleloscope computes 𝜃̂𝑖𝑟 by pooling counts across
(𝑡)
SNPs within the region for cell 𝑖, weighted by the current phasing 𝐼̂𝑗 , then updates the estimate of
(𝑡)

𝐼𝑗 by pooling 𝜃̂𝑖𝑟 across cells. The estimates of 𝜃𝑖𝑟 and 𝐼𝑗 usually converge within a few iterations.
If matched scDNA-seq data are available for a sample sequenced by scATAC-seq, 𝐼𝑗 can be
estimated from scDNA-seq and then used to compute 𝜃𝑖𝑟 for each cell in the scATAC-seq data,
enabling more information sharing between the two data types.
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The estimated major haplotype proportions (𝜃̂𝑖𝑟’s), along with a preliminarily normalized coverage
statistic (𝜌̃𝑖𝑟’s; Methods), are then used to identify a set of normal cells and diploid regions (Fig. 1,
Step 4). These control cells and regions are then used to obtain an improved coverage fold-change
(𝜌̂𝑖𝑟) for each cell and each region. If cell 𝑖’s true allele-specific copy numbers are homogeneous
within the given region 𝑟, then its true value of (𝜃𝑖𝑟 , 𝜌𝑖𝑟 ) should belong to the set of canonical points
displayed in Step 5 of Fig. 1. Thus, the estimated (𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 ) are clustered across cells and associated
with one of the canonical values to yield the cell-level haplotype profiles for region 𝑟. These celland region-specific haplotype profiles serve as the basis for clone assignment and subsequent
integration with peak signals in scATAC-seq data.
To improve sensitivity for the most difficult scenario of balanced mirrored subclones at small clonal
frequencies, Alleloscope allows an additional refinement step to improve the estimation of 𝜃̂𝑖𝑟, see
Supplementary Methods.

Validation using matched linked-read sequencing
First, we characterize the allelic heterogeneity of CNA events in 8 gastrointestinal tumors and 2
sections of a breast tumor (Supplementary Table 1) by applying Alleloscope to the scDNA-seq data
for these samples. To benchmark accuracy, we performed matched linked-read whole-genome
sequencing on five of the gastrointestinal tumor samples that represent different levels of
chromosomal instability. In linked-read sequencing, barcoded reads are derived from individual
high molecular weight DNA molecules, allowing the reconstruction of haplotypes covering
megabases in length [100-102]. We compared the haplotypes estimated by Alleloscope to the
haplotypes obtained from matched linked-read WGS to evaluate phasing accuracy. Then, we used
the linked-read haplotypes with Alleloscope to derive gold-standard allele-specific copy number
estimates for each cell, which are compared to those derived without the linked-read haplotypes
(Fig. 2a). This allows us to compute the sensitivity and specificity of our method (Supplementary
Methods).
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As illustration, consider the gastric cancer sample P5931. The heatmap in Fig. 2b gives a bird’seye-view of Alleloscope’s estimated profile for this sample, showing it to have a relatively simple
genome with few CNAs, which is expected given this tumor’s MSI status. However, detailed
inspection of the four chromosomes carrying clear CNA events, chr7, chr8, chr20, and chr21,
reveals surprising complexity at the allelic level. For each event, scatter plots of (𝜃̂𝑖𝑟 , 𝜌̂𝑖𝑟 ), colored
by haplotype-specific CNA state, are shown in Fig. 2c. Reassuringly, clusters align with the
canonical values (e.g. (1/2, 1) for diploid, (2/3, 1.5) for 1 copy major haplotype gain). For
chromosomes 7, 8, and 21, we find subclonal clusters differentiated by allelic ratios that would be
masked if we were to consider only total copy number. Let “M” be major and “m” be minor haplotype.
The chromosome 7 amplification exhibits two mirrored subclones with allelic configurations MMm
and Mmm. Chromosome 21 exhibits mirrored subclonal deletions (M- and m-). Four subclones are
revealed by the chromosome 8 amplification: MMm, Mmm, MMmm, and MMMm.
Comparing against the haplotypes derived from linked-reads, the phasing accuracy is 98% for the
chr21 deletion, ~90% for the two clonal amplifications (on chr8 and chr20), and 79% for the
subclonal chr7 amplification. Fig. 2d shows scatterplots of 𝜌̂𝑖𝑟 against major haplotype proportion
computed using linked-read haplotypes (𝜃̃𝑖𝑟), with cells colored by their state assignment from Fig.
2c (i.e. estimated without the linked-read information). Comparing Fig. 2d to Fig. 2c reveals that
Alleloscope’s allele-specific copy number state assignments, derived without external phasing
information, are almost exactly concordant ( ∼ 100% ) with those derived using linked-read
haplotypes. This shows that allele-specific copy number estimation in Alleloscope is, to a degree,
robust to errors in phasing.
On the detection of rare mirrored subclones, Alleloscope (with the refinement step) revealed an
amplification distinguishing two mirrored subclones each comprising <10 out of 700 cells on chr2
and chr3 of this sample; both events were confirmed by estimation using linked-read haplotypes
(Supplementary Fig. 1).
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CHISEL is the only other method for allele-specific copy number estimation with scDNA-seq data.
Thus, we benchmarked Alleloscope against CHISEL by comparing each method’s estimates under
default settings to the same method’s estimates using the true haplotypes provided by linked-read
WGS. Thus, each method’s performance is assessed using its own “gold standard” computed with
linked-read haplotypes. The sensitivity and specificity of both methods on each of the five samples
are given in Table 1. Overall, Alleloscope maintains high sensitivity and specificity across all
samples. Varying results obtained using different external phasing datasets and different block
sizes for CHISEL suggest that CHISEL’s accuracy depends on choices for these inputs
(Supplementary Table 2; Supplementary Fig. 2-3). More discussion on this benchmark study is
given in Supplementary Results.

Performance assessment via data downsampling and simulations
We also compared Alleloscope and CHISEL on the breast cancer sample that was analyzed by
Zaccaria and Raphael [91]. This sample does not have true phasing information, but was
sequenced at much higher coverage, and thus, we downsampled the reads to 50% and 25% of the
original depth and compared the estimates obtained from the downsampled datasets to those
obtained from the original dataset (Supplementary Results and Methods). At 25% of the original
depth, Alleloscope has specificity of 82% as compared to CHISEL’s 65%, and sensitivity of 95%
as compared to CHISEL’s 64% (Table 1) with the detailed heatmaps of the genome-wide profiles
shown in Supplementary Fig. 4.
Finally, we used simulations to investigate the performance of Alleloscope over a grid of
experimental parameters (number of cells, total per cell coverage, and total coverage at
heterozygous SNP sites, Supplementary Fig. 5). Across settings, Alleloscope attains higher
accuracy for deletions than for amplifications, which is expected given that the change in both
coverage ratio and major haplotype proportion (𝜃̂ ) is bigger for deletions. SNP phasing within
deletions (and other LOH events) is accurate across the board, but for amplifications it becomes
inaccurate at 10% and 5% clonal frequencies. CNA state assignment accuracy is, to some extent,
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robust to phasing error, and increases steadily with coverage, number of heterozygous SNPs, and
number of cells.

Pervasive occurrence of subclonal allele-specific CNAs
Alleloscope allows a comprehensive survey of the landscape of single-cell allele-specific copy
number profiles for the samples analyzed (Supplementary Table 1, Supplementary Figs. 6-12).
First consider copy-neutral LOH events, which are well-known drivers of cancer evolution that can
only be identified through allele-specific copy number analysis. Figure 3a shows an example of a
sample (P6198) which, according to 10x CellRanger, has whole genome duplication, but several
copy-neutral regions as marked. Consider chromosome 5, which seems to be copy neutral for its
entire length, yet bulk VAF clearly reveals a LOH in the q arm (Fig. 3b). Concordantly, Alleloscope
reveals a cluster centered at (𝜌, 𝜃) = (1,1), the canonical point for copy-neutral LOH, for this region
(Fig. 3b). All copy neutral LOH events identified by Alleloscope in this sample (chr5, chr11, chr16)
are validated by matched linked-read WGS (Supplementary Fig. 13).
Beyond copy-neutral LOH, we observe across samples a high prevalence of complex subclonal
CNAs. Prototypical examples from P6198, SNU601, P6335 and BC10X are shown in Fig. 3c. In
some regions, such as P6198 chromosome 9, SNU601 3q, BC10x 2q and 16p, allelic ratios
differentiate as many as seven subclonal clusters. Many such clusters vary only in allelic dosage,
not in total copy number. We find instances of minor subclones carrying deletion of one haplotype
coevolving with larger subclones carrying amplification of the other haplotype; such cases would
be missed by bulk-tissue analyses or by single-cell analyses using total coverage alone.
Recurrent chromosomal alterations affecting both haplotypes and producing gradients in haplotype
dosage are common across the samples. Consider, for example, the region on chromosome 9 of
P6198 (Fig. 3c), which reveals 7 subclones: besides the normal cell cluster and the dominant tumor
cell cluster with profile MMm, there is a small cluster with copy neutral LOH (MM), two small clusters
with 4 total copies (MMmm, MMMm) and two more with 5 total copies (MMMmm, MMMMm). This
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produces clones carrying major haplotype ratios that vary across the gradient {2 , 5 , 3 , 5 , 1}. Other
examples of such complexity include chromosome 3q of SNU 601 and chromosome 2q of BC10x,
also shown in Figure 3c. Interrogating the evolutionary route by which such diversity was achieved,
Alleloscope reveals that a whole genome doubling was likely in the histories of BC10x and P6198,
but not in the history of SNU601 (Supplementary Fig. 9&12). Thus, the subclones at 2q in BC10x
and 3q in SNU601 were likely achieved through different evolutionary routes: In BC10x, wholegenome doubling produced the MMmm subclone, from which the other subclones likely followed
through successive loss and gene conversion events. On the contrary, the clusters on 3q of
SNU601 were most likely produced by successive amplifications starting from the diploid genome.
Larger studies involving more samples would be needed to fully elucidate the evolutionary
dynamics of these complex regions.

Analysis of scATAC-seq with matched bulk WGS
To demonstrate the analysis of scATAC-seq data with Alleloscope, we first consider two basal cell
carcinoma samples with matched whole-exome sequencing (WES) data [103]. Using the matched
WES data, the genome of each sample was first segmented into regions of homogeneous bulk
copy number (Fig. 4a, middle panel shows the segmentation for SU008). For each cell in the
scATAC-seq data, Alleloscope then estimates the allele-specific copy number in each region.
Scatterplots of (𝜌̂, 𝜃̂ ) for five example CNA regions and one control region (chr12) from SU008 are
shown in Fig. 4a. For this sample, a standard peaks-based Uniform Manifold Approximation and
Projection (UMAP) embedding separates the cells confidently into three clusters: 308 tumor cells,
259 fibroblasts and 218 endothelial cells. Density contours for each cell type are shown in the
(𝜌̂, 𝜃̂ )- scatterplots (Fig. 4a). For each CNA region, Alleloscope’s (𝜌̂, 𝜃̂ )-plot clearly separates the
tumor cells from the normal fibroblast and endothelial cell populations, with the tumor cells clustered
around canonical points. This indicates that Alleloscope can accurately distinguish amplifications
and loss-of-heterozygosity events in low-coverage scATAC-seq data. In particular, Alleloscope
differentiated the cells that carry the putative copy-neutral LOH events in regions 4a, 6b, and 15b
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through shifts in major haplotype proportion. Note that normal cells, which are not expected to carry
chromosome-scale CNAs, exhibit chromosome-scale shifts in total coverage due to broad
chromatin remodeling but no significant difference in 𝜃̂𝑖𝑟, as exemplified by the chr6b region. Even
when comparing one normal cell type (fibroblasts) against another (endothelial cells), total
coverage can exhibit chromosome-scale shifts (Supplementary Fig. 14; Supplementary Methods).
This underscores the fact that relying solely on shifts in coverage, without complementary changes
in major haplotype proportion, is unreliable for copy number estimation in scATAC-seq data.
By assigning allele-specific CNA profiles to single cells in scATAC-seq data, Alleloscope allows the
integrative analysis of copy number and chromatin accessibility as follows (Fig. 4b): The scATACseq data, paired with bulk or single-cell DNA sequencing data, allows us to detect subclones. In
parallel, a peak-by-cell matrix can be generated following standard pipelines. Then, subclone
memberships or CNA profiles can be visualized on the low-dimensional embedding of the peak
matrix, and, conjointly, peak and transcription factor motif enrichment can be quantified at splits
along the clonal tree. Alleloscope also allows identification of significantly enriched/depleted peaks
after accounting for copy number differences, thus delineating events that are uniquely attributable
to chromatin remodeling.
Hierarchical clustering using major haplotype proportion 𝜃̂ identifies the tumor cells from the normal
cells for both SU006 (Supplementary Fig. 15) and SU008, and clearly delineates a subclone in
SU008 marked by a copy-neutral LOH event on chr4a (Fig. 4c). Focusing on SU008, we call the
cell lineage that carries the chr4a LOH event clone-2, and the other lineage clone-1. In parallel,
clustering by peaks cleanly separates the tumor cells from the epithelial cells and fibroblasts (Fig.
4d: left), and further, demarcates two distinct clusters in the tumor cells (peaks-1 and peaks-2) (Fig.
4d: middle). Coloring by chr4a major haplotype proportion (𝜃̂ ) on the peaks-derived UMAP shows
that the LOH in this region is carried by almost all of the cells in peaks-2 but only a subset of the
cells in peaks-1 (Fig. 4d: middle). This can also be clearly seen in the density of 𝜃̂ (Fig. 4d: right):
While 𝜃̂ is heavily concentrated near 1 for peaks-2, it is bimodal for peaks-1. Because clone-1 and
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clone-2 are differentiated by a copy-neutral event, this separation by peaks into two clusters is not
driven by broad differences in total copy number. Since clone-2 is split into two groups of distinct
peak signals, we infer that the chromatin remodeling underlying the divergence of the peaks-2 cells
is likely to have occurred in the clone-2 lineage, after the chr4a LOH event (Fig. 4e). In this way,
Alleloscope analysis of this scATAC-seq dataset allowed us to overlay two subpopulations defined
by peak signals with two subpopulations defined by a subclonal copy-neutral LOH.

Integrative analysis of a complex polyclonal population
The gastric cancer cell line SNU601 exhibits complex subclonal structure, as evidenced by multiple
multiallelic CNA regions (chr3e and chr18a shown in Fig. 3c). In addition to scDNA-seq, we also
performed scATAC-seq on this sample to profile the chromatin accessibility of 3,515 cells at mean
coverage of 73,845 fragments per cell. This allows us to compare the allele-specific copy number
profiles obtained by scATAC-seq with those given by scDNA-seq and integrate the two data types
in a multi-omic characterization of this complex tumor cell population.
First, we segmented the genome and estimated the allele-specific copy number profiles of single
cells at each segment for both the scATAC-seq and scDNA-seq data, following the procedure in
Fig. 1 with some modifications due to the lack of normal cells to use as control for this sample
(Methods). Fig. 5a shows the normalized total coverage, pooled across cells from scDNA-seq. Fig.
5b shows (𝜌̂, 𝜃̂ ) -scatterplots for five example CNA regions in scDNA-seq and scATAC-seq.
Compared to the scATAC-seq data, the scDNA-seq data has about 8-fold higher total read
coverage and 7-fold higher heterozygous site coverage per cell. Thus, whereas subclones
corresponding to distinct haplotype profiles are cleanly separated in the scDNA-seq data, they are
much more diffuse in the scATAC-seq data. Yet, cluster positions in scATAC-seq roughly match
those in scDNA-seq.
Fig. 5c shows the hierarchical clustering of cells from scDNA-seq based on their allele-specific copy
number profiles, revealing the subclonal structure and the co-segregating CNA events that mark
each subclone. For each cell in each region, Alleloscope also produces a confidence score for its
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copy number state assignment (Supplementary Fig. 16). Based on visual examination of the
confidence scores at the marker regions in both the ATAC and DNA sequencing data sets, we
chose 6 subclones for further investigation (Clones 1-6 labeled at the right of the heatmap). We
manually reconstructed the probable evolutionary tree relating these 6 clones to abide by the
following three rules:
(1) Parsimony: The tree with the least number of copy number events is preferred.
(2) Monotonicity: For a multi-allelic region with escalating amplifications (e.g. Mm, MMm, MMMm),
the states were reached in monotonic order (e.g. Mm→ MMm→ MMMm) unless a genome doubling
event occurred (in which case a sequence such as Mm→ MMmm→MMm would be allowed).
(3) Irreversibility of LOH: Once a clone completely loses an allele (i.e. copy number of that allele
becomes 0), it can no longer gain it back.
The evolutionary tree, thus derived, is shown in Fig. 6b. The mirrored-subclonal amplifications on
chr3q, the deletion on chr4p, and the multiallelic amplification on chr20q allowed us to infer the
early separation of clones 3-6 from clones 1-2. Subclones 3-6 are confidently delineated by
subsequent amplifications on chr3q, chr20q, chr11, chr13, and chr17. Note that high chromosomal
instability led to concurrent gains of 1q and 7p in both the Clone 1-2 and Clone 3-6 lineages. We
also observed a large number of low-frequency but high-confidence CNA events indicating that
ongoing chromosomal instability in this population is spawning new sporadic subclones that have
not had the chance to expand.
We now turn to scATAC-seq data, focusing on the 10 marker regions which, together, distinguish
Clones 1-6: chr1b, 3b-d, 4b, 7a, 11b, 13b, and 20b-c. The (𝜌̂, 𝜃̂ ) values allow direct assignment of
allele-specific copy number states to each cell for each region, with posterior confidence score. We
next performed subclone assignment to each cell via a Bayesian mixture model that pools
information across the 10 regions (Methods). Despite the low accuracy in per-region genotyping,
when information is pooled across the 10 marker regions, 81.6% of the 2,753 filtered cells can be
assigned to a subclone with >95% posterior confidence (Supplementary Fig. 17). These subclone
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assignments for each cell, and cell-level haplotype profiles for each region, can now be integrated
with peak-level signals. Following the scheme in Fig. 4b, we computed the UMAP coordinates for
the scATAC-seq cells based on their peak profiles (Fig. 6a). UMAP scatterplots colored by clone
assignment show that the 6 clones exhibit marked differences in their chromatin accessibility
profiles (Fig. 6a). We expect some of these peak-level differences to be driven by CNAs.
To delineate the peaks that differ between clones, and to identify peak differences that are not
accountable by CNAs, we developed a statistical test based on a generalized log-likelihood ratio
with adjustment parameters computed from the copy number profile of each of the two subclones
(Fig. 6b, Methods). The same test, but neglecting coverage adjustment, was also performed for
comparison. Along each branch, three numbers are shown —1. DAPs identified only before
adjustment; 2. DAPs identified both before and after adjustment; 3. DAPs identified only after
adjustment (Fig. 6b). For the smaller subclones (Clone 3,4,5), low coverage limits the detection
power and thus limits the DAP counts in both categories. Yet, juxtaposing DAP and CNA events
along the tumor phylogeny yields insights: Along most lineages, adjustment for CNA-induced shifts
in coverage removes a large number of peaks whose differential-accessibility signal is explainable
by the underlying change in copy numbers. This argues for the importance of CNAs as a
mechanism underlying subclonal differences in chromatin accessibility in this tumor.
Nevertheless, along some branches we find a large number of DAPs remaining after adjustment,
and thus must be due to other mechanisms. Notably, CNA adjustment also identifies new DAPs
whose signals were obscured by a change in copy number in the opposite direction. Two example
DAPs that remain significant after adjustment are shown as insets in Fig. 6b, with full list given in
Supplementary Table 3. The first example is a peak at the transcription start site (TSS) of the REC8
gene, which is located on chr14 where no apparent CNAs were observed across the six major
subclones. The TSS of REC8 is open in clones 3-6 but closed in clones 1-2 (p-value<0.0001).
REC8 is a gene encoding a meiosis-specific cohesion component that is normally suppressed in
mitotic proliferation, whose role in cancer has recently been subject to controversy: While Yu et al.
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[104] found the expression of this gene to suppress tumorigenicity in a gastric cancer cell line,
McFarlane et al. [105] postulated that it may be broadly activated in some cancers where it
generates LOH by reductional segregation. The opening of the TSS of REC8, stably maintained in
Clones 3-6, suggests that meiotic processes may underlie the increased chromosomal instability
of this multiclonal lineage. The second example is a peak at the TSS of the WWOX gene, located
on chr16, which is significantly depleted in Clone 3 (p-value<0.0001). Although chr16 has LOH
across all tumor cells, there are no detectable subclonal differences, and thus the decrease in
accessibility at WWOX for subclone 3 is not attributable to a copy number event. Because WWOX
is a well-known tumor suppressor whose down-regulation is associated with more advanced tumors
[106, 107], its decrease in accessibility suggests a more aggressive phenotype for Clone 3. These
two examples demonstrate how Alleloscope can be used to dissect the roles of CNA and
chromatin-level changes in the identification of gene targets for follow-up study.

Discussion
Despite recent advances in the application of single-cell sequencing to cancer, we are still far from
understanding the diversity of genomes that are undergoing selection at the single-cell level.
Notably, little is yet known about the intratumor diversity of allelic configurations within CNA regions,
and to what extent cell-to-cell heterogeneity in chromatin accessibility can be attributed to copy
number events. Here, we have developed Alleloscope, a method for allele-specific copy number
estimation that can be applied to single-cell DNA and ATAC sequencing data. Through a
combination of matched linked-reads whole genome sequencing, downsampling-based benchmark
experiments, and simulations, we assessed the accuracy of Alleloscope and benchmarked against
CHISEL, which is currently the only other method for scDNA-seq allele-specific copy number
profiling. Detailed discussion about the two methods can be found in Supplementary Results.
We applied Alleloscope to a panel of breast, colorectal, and gastric tumors and cancer cell lines,
where it revealed a yet under-explored level of allelic heterogeneity within hypermutable CNA
regions. We observed multiple instances of convergent evolution involving recurrent CNA events
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affecting the same region, some verified by linked read sequencing. In accordance with the findings
in Watkins et al. [108], we found that chromosomal instability drives the formation of subclones not
only in primary tumors but also after metastasis. Alleloscope was also applied to a scDNA-seq
dataset [57] generated from a different sequencing protocol (Supplementary Fig. 18;
Supplementary Methods), further demonstrating the general applicability of the approach.
Having established the allelic complexity of CNAs at single-cell resolution, we next applied
Alleloscope to scATAC-seq data to perform integrative study of copy number change and chromatin
remodeling. First, we considered the analysis of a public dataset consisting of two basal cell
carcinoma samples [63]. Here we showed that Alleloscope can detect amplifications, deletions,
and copy-neutral LOH events accurately in scATAC-seq data, and was able to find a subclone
delineated by a copy-neutral LOH event. Juxtaposing this subclone assignment with peak signals
allowed us to detect a wave of genome-wide chromatin remodeling in the lineage carrying the LOH.
Next, we applied Alleloscope to a complex polyclonal gastric cancer cell line with matched scDNAseq data. By overlaying peak signals with subclones delineated by varying allele-specific copy
number states, we were able to identify differentially accessible peaks that are not accountable by
copy number differences. Focusing on subclone-enriched peaks that are significant after copy
number adjustment allowed us to prioritize genes for follow-up.
Alleloscope can potentially be extended for single-cell data of other modalities, for example snmCseq [109] and scRNA-seq data, to investigate the relationships between clonal evolution, chromatin
remodeling, methylation, and transcriptome. To guide experimental design for single-cell omics
sequencing protocols, we investigated the performance of Alleloscope under different experimental
parameters. Among the parameters, coverage at heterozygous SNP sites is an especially important
consideration, especially for scATAC-seq and scRNA-seq where shifts in total coverage can be an
unreliable proxy for changes in DNA copy number. Most of the current scRNA-seq technologies
only sequence either the 3’ or 5’ end of the mRNA transcripts, which limits the number of
heterozygous SNP sites covered by reads. The latest developments in single-cell long read
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sequencing [110-112] and single-cell multimodal sequencing [113] bring forth new analysis
opportunities with this method.

Materials and Methods

ScDNA-seq datasets and pre-processing
The ten 10x scDNA-seq datasets analyzed in this study are summarized in Supplementary Table
1. P5931, P5847 and P6461 scDNA-seq data were generated using the method described in the
previous

study

[99].

We

applied

the

Cell

Ranger

(https://support.10xgenomics.com/single-cell-dna/software/overview/welcome;

DNA
beta

pipeline
version:

6002.16.0) for sample demultiplexing, read alignment, CNA calling and visualization. Most data
were aligned to the GRCh38 reference genome except for the two processed BC10x datasets
(GRCh37). For the tumor samples with a matched normal sample, the GATK HaplotypeCaller [114]
was used to call heterozygous SNPs on the matched normal samples. Otherwise, SNPs were
retrieved

on

the

tumor

sample

themselves.

Next,

we

applied

VarTrix

(https://github.com/10XGenomics/vartrix) to efficiently generate SNP-by-cell matrices for both
reference and alternative alleles of the identified SNPs.
To select high-quality SNPs, we filtered out the SNPs with <5 reads for P5846 and P5847, <10
reads for P5915 and P5931, <15 reads for P6335 and P6461, <20 reads for P6198, SNU601, and
the BC10X samples based on the number of SNP detected for each sample. Additionally, SNPs
located in the centromeres and telomeres were excluded. To exclude cells that are undergoing
apoptosis or mitosis, noisy cells labeled by the Cell Ranger tool were removed.

Single-cell ATAC datasets, sequencing and preprocessing
The scATAC-seq datasets analyzed in this study are summarized in Supplementary Table 4. We
used the following procedure to generate the SNU601 scATAC-seq dataset. About 400,000 cells
were washed with RPMI media and centrifuged (400g for 5 min at 4°C) twice. The supernatant was
removed and resuspended with chilled PBS + 0.04% BSA solution. The resuspended pellet was
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centrifuged (400g for 5min at 4°C), and the supernatant was removed again. Then 100 µL of chilled
Lysis Buffer (10 mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, 1% BSA, 0.1% Nonidet P40
Substitute, 0.1% Tween-20 and 0.01% digitonin) was added and carefully mixed 10 times. The tube
was incubated on ice for 7 min. After incubation, 1 mL of chilled Wash Buffer (10 mM Tris-HCl (pH
7.4), 10 mM NaCl, 3 mM MgCl 2, 1% BSA and 0.1% Tween-20) was added and mixed 5 times
followed by centrifugation of nuclei (500g for 5 min at 4°C). After removing the supernatant, nuclei
were resuspended in chilled Nuclei Buffer (10X Genomics), filtered by Flowmi Cell Strainer (40uM)
and counted using a Countess II FL Automated Cell Counter. Then the nuclei were immediately
used to generate scATAC-seq library.
ScATAC-seq library was generated using the Chromium Single Cell ATAC Library & Gel Bead Kit
(10X Genomics) following the manufacturer’s protocol. We targeted 3000 nuclei with 12 PCR cycles
for sample index PCR. The library was checked by 2% E-gel (Thermofisher Scientific) and
quantified using Qubit (Thermofisher Scientific). Sequencing was performed on Illumina
NextSeq500 using NextSeq 500/550 High Output Kit v2.5 (Illumina).
Raw sequencing reads of the SNU601 scATAC-seq sample was de-multiplexed with the 10x
Genomics Cell Ranger ATAC Software (v.1.2.0; https://support.10xgenomics.com/single-cellatac/software/pipelines/latest/algorithms/overview) and aligned to the GRCh38 reference genome.
The aligned scATAC-seq data of the two pre-treatment basal cell carcinoma samples (BCC; SU006
and SU008) were retrieved from GSE129785 [63]. To obtain all potential SNPs for the SU006 and
SU008 samples, GATK Mutect2 [115] was used to call single-nucleotide variants (SNVs) on the
bam files deduplicated by the Picard toolkits of both the t-cell dataset and the tumor dataset from
the same tumor. All SNVs from the paired tumor-normal datasets were combined and the read
counts of these SNPs were quantified for each cell in the tumor scATAC-seq dataset. For the
SNU601 scATAC-seq data, we instead quantified the read counts of the two alleles of the SNPs
more reliably called from the paired normal scDNA-seq data. Then the SNP-by-cell matrices for
both reference and alternative alleles were generated using Vartrix for all the scATAC-seq datasets.
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To select potential germline SNPs, we further filtered out the SNVs <5 reads for the SU008 sample
and <10 reads for the SU006 sample. SNPs with extreme VAF values <0.1 or >0.9 were also
excluded for both samples. Because we used the phasing information from the paired scDNA-seq
data to assist the estimation of the haplotype structures for the SNU601 scATAC-seq data, we did
not filter out SNPs with extreme VAF values for the scATAC-seq data. To improve the quality of
the downstream analysis for SNU601 scATAC-seq data, we filtered out cells <5 reads and the
SNPs <5 reads.

Linked-read sequencing and data processing
The five samples with the linked-read sequencing data were acquired as surgical resections
following informed consent under an approved institutional review board protocol from Stanford
University. Samples were subjected to mechanical and enzymatic dissociation as previously
described, followed by cryopreservation of dissociated cells33.
Cryofrozen cells were rapidly thawed in a bead bath at 37 ºC. Cell counts were obtained on a
BioRad TC20 cell counter (Biorad, Hercules, CA) using 1:1 trypan blue dilution. Between 1.5-2.5
million total cells were washed twice in PBS. Centrifugation was carried out at 400g for 5 minutes.
PBS was removed and cell pellets were frozen at -80ºC. DNA extraction was carried out on cell
pellets following thawing using either MagAttract HMW DNA Kit (P5931) or AllPrep DNA/RNA Mini
Kit (Qiagen Inc., Germantown, MD, USA) as per manufacturer’s protocol. Quantification was
carried out using Qubit (Thermofisher Scientific).
Sequencing libraries were prepared from DNA using Chromium Genome Reagent Kit (v2
Chemistry) (10X Genomics, Pleasanton, CA, USA) following manufacturer’s instructions.
Sequencing was performed using Illumina HiSeq or NovaSeq sequencers using 150x150 bp
paired-end sequencing and i7 index read of 8 bp. Long Ranger (10X Genomics; v2.2.0) was used
to align reads, call and phase SNPs, indels and structural variants.
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Segmentation
The first step of Alleloscope is to segment the genome into regions with different CNA profiles. The
appropriate segmentation algorithm depends on what samples are available. First, matched bulk
DNA sequencing data (WGS/WES) or pseudo-bulk data from scDNA-seq data can be segmented
using FACLON [48], a segmentation method that jointly models the bulk coverage and bulk VAF
profiles, if a matched normal sample is available. To accommodate segments from rare subclones,
methods that integrate shared cellular breakpoints in CNA detection for scDNA-seq [80] can
improve sensitivity. If a normal sample is unavailable, Alleloscope instead uses an HMM-based
segmentation method. The HMM method, which operates on the binned counts of pooled cells,
assumes a Markov transition matrix on four hidden states representing deletion, copy-neutral state,
1 − 3𝑡
𝑡
single-copy amplification and double-copy amplification: (
𝑡
𝑡

𝑡
1 − 3𝑡
𝑡
𝑡

𝑡
𝑡
1 − 3𝑡
𝑡

𝑡
𝑡
),
𝑡
1 − 3𝑡

where 𝑡 = 1 × 10−6 by default. Emission probabilities follow a normal distribution with means {1.8,
1.2, 1, 0.5} and standard deviation 0.2. The segmentation plots in the study were generated by the
HMM algorithm. With the paired sample, the P6198 tumor sample was segmented using FALCON
on SNPs >30 reads with default parameters. Besides FALCON and HMM, users can choose the
methods that work best for specific datasets. For example, ASCAT [92] on the P6198 sample yields
similar results (Supplementary Fig. 9).

Whole-exome sequencing (WES) data processing
The WES data of the two paired tumor-normal samples (SU006 and SU008) were obtained from
PRJNA533341 [103]. Raw fastq files were aligned to the GRCh37 reference genome using bwamem [116] with duplicate reads removed using the Picard toolkits [117]. The copy number calls of
paired normal-tumor samples were obtained using Varscan2 [118]. Then the HMM algorithm was
applied for segmentation.
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SNP phasing and single-cell allele profile estimation per region
For each region 𝑟 after segmentation, an expectation-maximization (EM)-based method is used to
iteratively phase each SNP and estimate cell-specific allele-specific copy number states. Recall
that “Major haplotype” is defined as the haplotype with higher aggregate copy number in the sample.
Let 𝐼𝑗 indicate whether the reference allele of SNP 𝑗 is located on the major haplotype and 𝜃𝑖𝑟
denote major haplotype proportion of cell 𝑖 for region 𝑟. The complete log-likelihood of the model is
𝑛

𝑙(𝜃𝑖𝑟 ) = ∑ 𝑙𝑜𝑔𝑃(𝐴𝑖𝑗 , 𝐵𝑖𝑗 |𝜃𝑖𝑟 )
𝑗=1
𝑛

= ∑{[𝐴𝑖𝑗 𝑙𝑜𝑔𝜃𝑖𝑟 + 𝐵𝑖𝑗 log(1 − 𝜃𝑖𝑟 )]𝐼𝑗 + [𝐵𝑖𝑗 𝑙𝑜𝑔𝜃𝑖𝑟 + 𝐴𝑖𝑗 log(1 − 𝜃𝑖𝑟 )](1 − 𝐼𝑗 )}
𝑗=1

where 𝐴𝑖𝑗 and 𝐵𝑖𝑗 are the observed read counts for the reference and alternative alleles of cell 𝑖 on
SNP 𝑗. In the E-step, we calculate the conditional expectation of the hidden variable 𝐼𝑗 .

𝐸𝜽̂

𝒊𝒓

(𝑡)
=
(𝑡) [𝐼𝑗 |𝐴𝑖𝑗 , 𝐵𝑖𝑗 ] = 𝐼̂𝑗

(𝑡)
∏𝑖 𝜃̂𝑖𝑟
(𝑡)
∏𝑖 𝜃̂𝑖𝑟

𝐴𝑖𝑗

𝐴𝑖𝑗

(𝑡)
(1 − 𝜃̂𝑖𝑟 )

(𝑡)
(1 − 𝜃̂𝑖𝑟 )

𝐵𝑖𝑗

𝐵𝑖𝑗

(𝑡)
+ ∏𝑖 (1 − 𝜃̂𝑖𝑟 )

𝐴𝑖𝑗 (𝑡) 𝐵𝑖𝑗
𝜃̂𝑖𝑟

(𝑡)
where 𝜃̂𝑖𝑟 is the parameter from the tth iteration. In the M-step, 𝜃̂𝑖𝑟 is updated by solving
(𝑡+1)
(𝑡)
𝜃̂𝑖𝑟
= 𝑎𝑟𝑔𝑚𝑎𝑥𝜃𝑖𝑟 𝐸[𝑙(𝜃𝑖𝑟 )|𝐴𝑖𝑗 , 𝐵𝑖𝑗 , 𝜃̂𝑖𝑟 ]
(𝑡)

=

(0)

An initial estimate 𝐼̂𝑗

(𝑡)

∑𝑗[𝐴𝑖𝑗 𝐼̂𝑗 + 𝐵𝑖𝑗 (1 − 𝐼̂𝑗 )]

.

∑𝑗[𝐴𝑖𝑗 𝐼̂𝑗(𝑡) + 𝐵𝑖𝑗 (1 − 𝐼̂𝑗(𝑡) )] + ∑𝑗 [𝐴𝑖𝑗 (1 − 𝐼̂𝑗(𝑡) ) + 𝐵𝑖𝑗 𝐼̂𝑗(𝑡) ]

is derived from the bulk VAF profile, and the two steps are iterated until

convergence. For the SNU601 scATAC-seq dataset, the phases estimated in the paired scDNAseq dataset (𝐼̂𝑗’s) were directly applied to estimate the 𝜃̂𝑖𝑟’s of the cells in the scATAC-seq data. To
reduce noise from low-coverage SNPs, we only used cells with ≥ 20 reads covering the identified
SNPs for each region.
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Selecting normal cells and normal regions for single-cell coverage normalization
To compute the relative coverage change for each cell in region 𝑟 (𝜌̂𝑖𝑟), normal cells and diploid
regions are required for normalization. The 𝜃̂𝑖𝑟’s estimated above are used to identify normal cells
and diploid regions. To identify normal cells, all cells were first clustered by hierarchical clustering.
For each cell cluster, we compute a score 𝑑𝑐 that is the sum, across regions, of a per-region metric
quantifying the mean deviation of 𝜃̂𝑖𝑟 from 0.5 (the normal value):
𝑅

2
∑𝑖∈𝑆𝑐 𝜃̂𝑖𝑟
Δ𝑐 = ∑ |
− 0.5|
𝑛𝑐
𝑟=1

where 𝑆𝑐 is the set of cells in cluster 𝑐, and 𝑛𝑐 = |𝑆𝑐 |. We then identify the cluster 𝑐 ∗ = 𝑎𝑟𝑔𝑚𝑖𝑛𝑐 Δ𝑐 .
All cells in 𝑐 ∗ are considered normal.
Putative diploid regions are identified using both 𝜃̂𝑖𝑟 and coverage. First, Alleloscope computes
2
𝑑𝑐𝑟 = ∑|𝜃̂𝑖𝑟 − 0.5| ,
𝑖∈𝑆𝑐

where high values of 𝑑𝑐𝑟 are evidence for the allelic imbalance of cluster 𝑐 in region 𝑟. Because
regions with both haplotypes equally amplified can also have small 𝑑𝑐𝑟 , we also compute an
adjusted coverage ratio (𝜌̃𝑖𝑟; defined as below),
𝜌̃𝑖𝑟 =

𝑁𝑖𝑟 𝐿𝑟
× ,
𝑁𝑖
𝐿

where 𝑁𝑖𝑟 is the total read count for cell 𝑖 and region 𝑟, and 𝑁𝑖 is the total read count for cell 𝑖 across
regions. 𝐿𝑟 is the length of the region 𝑟 and 𝐿 is the total length of the genome. For region 𝑟, cells
with 𝜌̃𝑖𝑟 values larger than the 99th percentile are assigned to the 99th percentile value. We then
compute the cluster mean 𝜌̃𝑖𝑟 for each region 𝑟,
𝑚𝑐𝑟 =

∑𝑖∈𝑆𝑐 𝜌̃𝑖𝑟
.
𝑛𝑐

Alleloscope identifies potential diploid regions for each cluster by first ranking by 𝑑𝑐𝑟 to identify the
clusters with the smallest 𝑑𝑐𝑟 , and among these, identify clusters with low 𝑚𝑐𝑟 . These regions are
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proposed as candidate diploid regions for visual inspection before it is used to compute normalized
coverage ratios for each cell in the cluster.
Because coverage on scATAC-seq data is confounded by epigenetic signals, chromosome 22 for
SU008 and chromosome 18 for SU006 were selected manually as normal regions based on their
VAF and relative coverage values in the matched WES data. Cells were considered as normal or
tumor cells based on peak-based clustering. For the SNU601 scATAC-seq dataset, chromosome
10 was selected as the normal region based on the above procedure applied to the matched
scDNA-seq data.

Cell-level CNA state estimation
The cell-level allele-specific copy number profiles are defined by both relative coverage
change (𝜌̂𝑖𝑟 ) and major haplotype proportion (𝜃̂𝑖𝑟) for region 𝑟. After the normal cells and control
region are identified, cell-specific relative coverage change in region r is calculated as

𝜌̂𝑖𝑟 =

𝑁𝑖𝑟
𝑁0𝑟
/ 𝑚𝑒𝑑𝑖𝑎𝑛(
)
𝑁𝑖0
𝑁00

where 𝑁𝑖𝑟 is total read counts in region 𝑟 and 𝑁𝑖0 is total read counts in a reference region for cell
𝑖. 𝑁0𝑟 is a vector denoting total read counts in region 𝑟 of all identified normal cells and 𝑁00 is a
vector denoting total read counts in the same reference region of all identified normal cells. For
P6461 with no diploid region, 𝜌̂𝑖𝑟 was multiplied by 2 for the abnormal cells. Because SNU601 is a
tumor cell line with no normal cells in the dataset, for its scDNA-seq data, 𝑁0𝑟 and 𝑁00 were
calculated from the cells in the P6198 sample instead. For SNU601 scATAC-seq data, we aligned
the distribution of the 𝜌̂𝑖𝑟 values in the paired scDNA-seq data to the distribution of the

𝑁𝑖𝑟
𝑁𝑖

values

for each region to get the normalized 𝜌̂𝑖𝑟 in the scATAC-seq data. The normalized 𝜌̂𝑖𝑟 values for
the scATAC-seq data were computed by
𝑎𝑡𝑎𝑐
𝜌̂𝑖𝑟
=

𝑁𝑖𝑟
𝑁𝑖𝑟
𝑑𝑛𝑎
/ 𝑚𝑒𝑑𝑖𝑎𝑛( ) × 𝑚𝑒𝑑𝑖𝑎𝑛(𝜌̂𝑖𝑟
)
𝑁𝑖0
𝑁𝑖0
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Cells with extreme 𝜌̂𝑖𝑟 values (above 99th percentile and below 1 percentile) were excluded for each
region. With the (𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 ) pairs, cells in the scDNA-seq data can be classified into haplotype profile 𝑔
with the expected (𝜌𝑔 , 𝜃𝑔 ) values based on minimum distance. With noisier signals in the scATACseq data, the haplotype structures identified in the paired scDNA-seq data are used to guide the
genotyping for each region. For region 𝑟, the posterior probability that cell 𝑖 carries haplotype profile
𝑔 is

𝑃(𝐺𝑇𝑖𝑟 = 𝑔𝑟 |𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 ) =

𝑃(𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟|𝐺𝑇𝑖𝑟 = 𝑔𝑟 )𝜋𝑔𝑟
,
∑𝑔 ′ 𝑃(𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 |𝐺𝑇𝑖𝑟 = 𝑔′ )𝜋𝑔′
𝑟

𝑟

where 𝑔𝑟 denotes the haplotype profile observed in region 𝑟 in the paired scDNA-seq data and 𝜋𝑔𝑟
denotes the prior probability that a randomly sampled cell carrying the 𝑔𝑟 haplotype profile. A
uniform prior was used for 𝜋𝑔𝑟 . In the formula,

𝑃(𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 |𝐺𝑇𝑖𝑟 = 𝑔𝑟 ) = 𝑃(𝜌̂𝑖𝑟|𝜇 = 𝜌𝑔 ; 𝜎𝜌 = 0.25) × 𝑃 (𝜃̂𝑖𝑟|𝜇 = 𝜃𝑔 ; 𝜎 = √

𝜃̂𝑖𝑟 (1 − 𝜃̂𝑖𝑟 )
),
𝑛𝑖𝑟

where 𝑛𝑖𝑟 is total read count in region 𝑟 for cell 𝑖. For scATAC-seq data, the haplotype profile of cell
𝑖 in region 𝑟 was estimated by maximizing the above posterior probability.

Validations using matched linked-read sequencing data for each region
We performed validations on five samples using matched linked-read sequencing data. Two
strategies were used for the validations. First, to assess the phasing accuracy of region r, the
largest haplotype block within region 𝑟 in the matched linked-read sequencing data was selected
for comparison, ensuring that the included SNPs are phased with respect to one another. Then the
𝐼̂𝑗 estimates for SNPs within region 𝑟 in the scDNA-seq data were converted to binary indicator 𝐼̃𝑗
𝐼̃𝑗 = 1(𝐼̂𝑗 > 0.5) ∈ {0,1}
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Using the major/minor haplotype setting, all SNPs in the largest haplotype block in the matched
linked-read sequencing data were placed accordingly to retried 𝐼𝑗 as the gold standard. Comparing
the binary estimates 𝐼̃𝑗 and 𝐼𝑗 , the phasing accuracy for region 𝑟 was computed as follows:

𝐴𝐶𝐶𝑟,𝑝ℎ𝑎𝑠𝑖𝑛𝑔 =

∑ 1 (𝐼̃𝑗 = 𝐼𝑗 ; 𝐼̃𝑗 ∈ 𝐼𝑗 )
,
∑ 1(𝐼̃𝑗 ∈ 𝐼𝑗 )

Secondly, we evaluated the accuracy for cell-level CNA state estimation for region 𝑟. To do this, for
each cell in region 𝑟 we compared the estimated haplotype profiles (𝜃̂𝑖𝑟) to the haplotype profiles
(𝜃𝑖𝑟) obtained by plugging in known phases provided by the matched linked-read sequencing data
as the gold standard. Similarly, the haplotype block with the largest number of SNPs was used
here. The 𝜃𝑖𝑟’s, used as the gold standard, were retrieved by directly plugging in known phases 𝐼𝑗 ,
provided by the matched linked-read sequencing data (explained in the first strategy). Then the
accuracy for cell-level CNA state estimation of region 𝑟 is computed as

𝐴𝐶𝐶𝑟,𝐶𝑁𝐴𝑠𝑡𝑎𝑡𝑒 =

∑𝑖 1(𝜃̂𝑖𝑟 = 𝜃𝑖𝑟 )
.
∑𝑖 𝑖

Cell Lineage Reconstruction
For scDNA-seq data, cell-specific haplotype profiles from Alleloscope across the genome are used
to reconstruct cell lineage trees. The “Gower’s distance” is calculated using “cluster” R package on
the nominal haplotype profiles between cells. The ‘pheatmap’ R package was used to perform
hierarchical clustering on the distance using the “ward.D2” method. Because fewer SNPs lead to
higher variance in 𝜃̂𝑖𝑟’s, we by default included segments with more than 2,000 SNPs identified.
For visualization, each segment was plotted with its length proportional to 5,000,000 bins, and the
heights of the clustering tree were log-transformed.
To explore tumor subclonal structure in the two BCC scATAC-seq datasets, we instead clustered
the cells using 𝜃̂𝑖𝑟 values, which are orthogonal to the CNA signals based on total coverage, across
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the segments with more than 500 SNPs. Then, hierarchical clustering is performed on the
Euclidean distance using the “ward.D2” method.
Because the subclones for the SNU601 sample were identified first from the scDNA-seq data, we
adopted a supervised strategy to assign each cell in the SNU601 scATAC-seq dataset into different
subclones. First, we identified 10 marker regions-- chr1b, 3b-d, 4b, 7a, 11b, 13b, and 20b-c that
differentiate the cells into the six major subclones based on the subclone specific copy number
profiles from the scDNA-seq data. Combining the haplotype profiles across the ten regions for each
cell enables assignment of the cells into one of the six subclones with high confidence. The
posterior probability of cell 𝑖 coming from clone 𝑘 was

𝑃(𝐶𝑙𝑜𝑛𝑒𝑖 = 𝑘|𝜌̂𝑖 , 𝜃̂𝑖) =

𝑃(𝜌̂𝑖 , 𝜃̂𝑖|𝐶𝑙𝑜𝑛𝑒𝑖 = 𝑘)𝜋𝑘
,
∑𝑘′ 𝑃(𝜌̂𝑖 , 𝜃̂𝑖|𝐶𝑙𝑜𝑛𝑒𝑖 = 𝑘 ′ )𝜋𝑘 ′

where 𝑘 ∈ {1~6} for the six clones and 𝜋𝑘 is the prior probability that a randomly sampled cell
coming from the 𝑘 𝑡ℎ clone, which was set to uniform in the analysis. In the formula,

𝑃(𝜌̂𝑖 , 𝜃̂𝑖 |𝐶𝑙𝑜𝑛𝑒𝑖 = 𝑘) = ∏ 𝑃(𝜃̂𝑖𝑥 , 𝜌̂𝑖𝑥 |𝐶𝑙𝑜𝑛𝑒𝑖 = 𝑘) = ∏ 𝜙 (
𝑥

𝑥

𝜃̂𝑖𝑥 − 𝜃𝑘𝑥
√𝑛𝑖𝑥 𝜃𝑘𝑥 (1 − 𝜃𝑘𝑥 )

)𝜙 (

𝜌̂𝑖𝑥 − 𝜌𝑘𝑥
),
𝜎𝜌

where 𝑥 indexes the ten marker regions; 𝜃̂𝑖𝑥 and 𝜌̂𝑖𝑥 are the estimated major haplotype proportion
and relative coverage for cell 𝑖 in the scATAC-seq data; 𝜃𝑘𝑥 and 𝜌𝑘𝑥 are the “known values” for
specific haplotype profiles for clone 𝑘 derived from the paired scDNA-seq data; and 𝑛𝑖𝑥 is the
number of total read counts in the 𝑥 𝑡ℎ marker region for cell 𝑖. Each cell was assigned into one of
the six subclones by maximizing the posterior probability with the confidence score being the
posterior probability of the assigned clone.

ScATAC-seq data analysis
To investigate the relationships between allele-specific CNAs and chromatin accessibility, we
processed the peak signals in addition to the allele-specific CNAs for each cell in the scATAC-seq
data. For the two public BCC samples, the peak-by-cell matrices were obtained from GSE129785.
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We log-transformed the count matrices, selected the peaks in >10% cells, regressed out cell total
coverage for each peak by linear regression, and projected the cells onto the UMAP plot using
genome-wide peak signals [119]. The cell type identity for each cluster was retrieved from the
previous study [63]. To further explore intratumor heterogeneity, we selected the cells labeled as
tumor cells, repeated the pre-processing steps described above, and projected the tumor cells onto
the UMAP plot.
For the SNU601 scATAC-seq dataset, scATAC-pro [120] was used to call peaks and generate the
peak-by-cell matrix. We first filtered out the cells that have proportions of fragments on the detected
peaks <0.4 and total peaks outside of the range 15,000~100,000, and filtered out the peaks
observed in less than 10% of cells. After the matrix was log-transformed, we regressed out cell
total coverage for each peak by linear regression. Using Louvain clustering, two clusters with
extreme total fragment counts were removed. After cell filtering, we repeated the process and
projected the cells onto the UMAP plot. The cells are then colored by the clonal assignment based
on the DNA information.

Differentially accessible peaks (DAPs) identification with copy number adjustment for
scATAC-seq data
To identify differentially accessible peaks (DAPs) after accounting for copy number differences
between two clones, we developed a statistical test based on a generalized log-likelihood ratio
(GLLR) statistic. We first define some necessary terms: Given a segmentation of the genome, for
a given clone 𝑐, let 𝜃𝑐 = {(𝐿𝑅 , 𝑍𝑅 )} be the copy number profile, which can be expressed as a vector
of region lengths (𝐿𝑅 ) and average copy numbers (𝑍𝑅 ) across all regions 𝑅. For peak 𝑘, we define
function 𝑓𝑘 (𝜃𝑐 ) to be the proportion of genomic DNA in the peak region based on the copy number
profile of clone 𝑐, computed as follows:

𝑓𝑘 (𝜃𝑐 ) =

𝐿𝑟(𝑘) 𝑍𝑟(𝑘)
𝑙𝑘
×
,
∑𝑟 𝐿𝑟 𝑍𝑟
𝐿𝑟(𝑘)

where 𝑟(𝑘) is the region 𝑟 to which peak 𝑘 belongs and 𝑙𝑟 is the length of peak 𝑘.
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For peak k and clone 𝑐, let 𝑌𝑐𝑘 be the total read count across the cells in the clone, and let 𝑁𝑐 be
the total read count across all peaks summed across the cells in the clone. 𝑌𝑐𝑔 can be modeled by
Binomial sampling,
𝑌𝑐𝑘 ∼ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑐 , 𝑓𝑘 (𝜃𝑐 )𝑝𝑐𝑘 ),
where, 𝑝𝑐𝑘 is the relative probability of detecting reads in the peak k region after adjusting for the
copy numbers. Between clones with different copy number profiles, differences in 𝑝𝑐𝑘 are evidence
for chromatin remodeling. Thus, pairwise comparisons were performed for each branch (clone 𝑐1
versus clone 𝑐2 ) and for each peak, using the generalized likelihood ratio test with the hypothesis
𝐻0 : 𝑝𝑐1𝑘 = 𝑝𝑐2 𝑘 =𝑑𝑒𝑓 𝑝0𝑘 and 𝐻1 : 𝑝𝑐1 𝑘 ≠ 𝑝𝑐2 𝑘 .
We compute the GLLR test statistic as below,
max 𝑙(𝑝0𝑘 )

𝐿𝐿𝑅𝑘 = −2 log

𝑝0𝑘 ∈𝑝

max

𝑝𝑐1𝑘 ; 𝑝𝑐2𝑘 ∈𝑝

𝑙(𝑝𝑐1𝑘, , 𝑝𝑐2 𝑘, )

= 2ℓ(𝑝̂𝑐1𝑘 , 𝑝̂𝑐2 𝑘 ) − 2ℓ(𝑝̂0𝑘 )~𝑋12 ,

Which follows the Chi-squared distribution (see Supplementary Methods for derivation of MLE).
Using the GLRT, a peak is considered as a DAP if its FDR adjusted p-value<0.01 for the pairwise
clonal comparison.
Simultaneously, the GLRT under the binomial model without copy number adjustment was also
performed for comparison:
𝑌𝑐𝑘 ∼ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑐 , 𝑝𝑐𝑘 ),
The same criterion was used to identify DAPs for each pairwise clonal comparison (FDR adjusted
p-values<0.01). To identify genes potentially regulated by DAPs, we searched the genes with TSS
within ± 2,000 bp distance of each DAP.
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Figures

Figure 2.1: Overview of allele-specific copy number estimation of single-cells with
Alleloscope.
1. The algorithm operates on raw read count matrices for reference allele (Ref) and alternative
allele (Alt) computed from single-cell DNA or ATAC sequencing. 2. First, we obtain a segmentation
of the genome based on sample-matched whole genome or whole exome sequencing data using
FALCON [48]. If scDNA-seq is available, cells can be pooled to derive a pseudo-bulk. 3. We first
define 𝜃̂𝑖𝑟 as the major haplotype proportion for cell 𝑖 for region 𝑟 derived from the segmentation.
Then for each region 𝑟, Alleloscope simultaneously phases SNPs (𝐼̂𝑗 ) and estimates cell major
haplotype proportion (𝜃̂𝑖𝑟) by expectation maximization (EM) algorithm. In the E-step, information
is pooled across cells to estimate the phasing of each SNP. In the M-step, information is pooled
across all SNPs in the region are pooled to estimate the major haplotype proportion 𝜃̂𝑖𝑟 for each
cell. The toy example shows a scenario with two cells for a region containing 5 SNPs, with cell 2
carrying an amplification of the major haplotype (in pink). For each cell and each SNP, alleles that
are observed in a sequenced read are bolded in black (we assume that only one read is observed,
reflecting the sparsity of the data). The true phase (𝐼𝑗 ) of the SNPs and the true major haplotype
proportion (𝜃𝑖𝑟 ) are shown. 4. After 𝜃̂𝑖𝑟 are estimated for each region 𝑟, 𝜃̂𝑖𝑟’s are pooled across all
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regions to identify candidate normal cells and candidate normal regions for computing a normalized
coverage 𝜌̂𝑖𝑟 for region 𝑟 in cell 𝑖. Matched normal can be specified if available. 5. Alleloscope
assigns integer allele-specific copy numbers to each cell for each region based on the (𝜌̂𝑖𝑟, 𝜃̂𝑖𝑟 )
pairs.
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Figure 2.2: Validation of the Alleloscope results on the P5931 gastric cancer patient sample
and linked-read sequencing data.
(a) Illustration of the validation scheme using linked-read sequencing data. Phasing accuracy and
accuracy in allele-specific copy number state estimation are used to access the performance of the
method. (b) Hierarchical clustering of cells in the P5931t sample based on allele-specific copy
numbers given by Alleloscope, showing normal cells and 4 main clones, as well as a number of
small clones marked by highly confident low-frequency mutations. M: Major haplotype, m: minor
haplotype. (c) (𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 ) estimated by Alleloscope for four regions, colored by the inferred haplotype
profile. Note that clusters fall on canonical points corresponding to discrete allele-specific copy
number configurations. Phasing accuracy for each region is shown in the plot title. In the color
legend, M and m represent the “Major haplotype” and “minor haplotype” respectively. (d) Similar to
(c), with 𝜃̃𝑖𝑟 estimated using known SNP phases from matched linked-read sequencing data,
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colored by the haplotype profiles assigned in (c) using Alleloscope without the given phasing
information. Accuracy in allele-specific copy number state estimation (Genotyping accuracy) is
labeled in the plots.
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Figure 2.3: Across multiple cancer types, Alleloscope detects loss-of-heterozygosity events
and multi-allelic copy number aberrations, delineating complex subclonal structure which
are invisible to total copy number analysis.
(a) The Cell Ranger hierarchical clustering result for P6198t with copy-neutral regions labeled (total
512 cells). (b) Top: FALCON segmentation of P6198 chr5 into two regions with different allelespecific copy number profiles. Bottom: Detailed haplotype profiles of the two regions from
Alleloscope, showing that the first region is diploid across cells and the second region has a lossof-heterozygosity for a subpopulation of cells. The a and b following the chromosome number
denote two ordered segments. (c) Single-cell allele-specific estimates (𝜌̂, 𝜃̂ ), colored by assigned
haplotype profiles, for select regions in the samples P6198t (metastasized colorectal cancer
sample), SNU601 (gastric cancer cell line), P6335 (colorectal cancer sample), and BC10X (breast
cancer cell line). In the color legend, M and m represent the “Major haplotype” and “minor haplotype”
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respectively. The lower-case letters following the chromosome number in the titles denote the
ordered genomic segments.
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Figure 2.4: Alleloscope multiomic analysis of scATAC-seq data of a basal cell carcinoma
sample (SU008).
(a) Genotype profiles for six example regions for cells in scATAC-seq data. The regions are taken
from segmentation of matched whole exome sequencing (WES) data. Each dot represents a cellspecific (𝜌̂𝑖𝑟, 𝜃̂𝑖𝑟 ) pair. Cells are colored by annotation derived from peak signals[63], Tumor: tumor
cells, Fibro: fibroblasts, Endo: Endothelial cells]. Density contours are computed for each cell type
(tumor, fibroblasts, endothelial) separately and shown by color on the plot. The lower-case letters
following the chromosome number in the titles denote the ordered genomic segments. (b) Pipeline
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for multi-omics analysis integrating allele-specific copy number estimates and chromatin
accessibility peak signals on ATAC-seq data. (c) Hierarchical clustering of cells by major haplotype
proportion (𝜃̂ ) allows the separation of tumor cells from normal cells, as well as the differentiation
of a subclone within the tumor cells. The marker region on chr4a separating the two tumor
subclones is highlighted. (d) Integrated visualization of chr4a major haplotype proportion (𝜃̂𝑖𝑟 ) and
genome-wide peak profile. Left: UMAP projection of the 788 cells in the dataset by their genomewide peak profile, colored by 𝜃̂𝑖𝑟. The cell type annotation (endothelial, fibroblasts, and tumor cells)
is labeled in the plot. Middle: UMAP projection of only the 308 tumor cells by their genome-wide
peak profile shows two well-separated clusters: peaks1 and peaks2. Right: Density of 𝜃̂𝑖𝑟 values
for the peaks1 and peaks2 subpopulations. (e) Intratumor heterogeneity of SU008 is shaped by a
subclonal LOH of chr4a followed by subsequent genome-wide chromatin remodeling leading to
three subpopulations: Clone 1 which does not carry the chr4a LOH (peaks cluster 1), Clone 2
carrying the chr4a LOH (peaks cluster 1), and remodeled clone 2 (peaks cluster 2).
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Figure 2.5: Alleloscope analysis of scDNA-seq and scATAC-seq data reveals complex
subclonal heterogeneity in the SNU601 gastric cancer cell line.
(a) Genome segmentation using HMM on the pooled total coverage profile computed from scDNAseq data. (b) Single-cell allele-specific copy number profiles (𝜌̂, 𝜃̂ ) for five regions in scDNA-seq
and scATAC-seq data. Cells are colored by haplotype profiles according to legend in Fig. 5c. (c)
Tumor subclones revealed by hierarchical clustering of allele-specific copy number profiles from
the scDNA-seq data. Genotypes of the five regions shown in Fig. 5b, for three example cells, are
shown in the left. The haplotype structures for the 5 regions in Fig. 5b of three cells randomly
chosen from Clone 1, 2, and 3, are shown to the left of the heatmap. In the color legend, M and m
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represent the “Major haplotype” and “minor haplotype” respectively. The six clones selected for
downstream analysis in scATAC-seq data are labeled in the plot.
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Figure 2.6: Integrative analysis of allele-specific copy number and chromatin accessibility
for SNU601 ATAC sequencing data.
(a) UMAP projection of genome-wide scATAC-seq peak profile on 2,753 cells. The same group of
cells were clustered into one of the six subclones based on their allele-specific copy number profiles
across the 10 selected regions. Cells in different subclones are labeled with different colors, using
the same color scheme as that for the subclone labels in Fig. 4c. The number of cells colored in
each UMAP is shown at the bottom-right corners. (b) A highly probable lineage history of SNU601,
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with copy number alterations (CNAs) and differentially accessibility peaks (DAPs) marked along
each branch. P-values of the tests for association between DAPs and CNAs are shown along each
branch. For two example DAP genes, pooled peak signals for each subclone are shown as inset
plots.
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Tables
Table 2.1: Comparison between Alleloscope and CHISEL using two benchmark strategies.

Dataset

Method

Sensitivity

Specificity

Benchmark with matched linked-read sequencing data
P5915

P5931

P6198

P6335

Alleloscope

0.9373

0.9915

CHISEL
(before correction)

0.7284

0.9757

CHISEL
(after correction)

0.7786

0.9722

Alleloscope

0.9402

0.9986

CHISEL
(before correction)

0.7520

0.9434

CHISEL
(after correction)

0.0112

0.9508

Alleloscope

0.9433

0.9666

CHISEL
(before correction)

0.9397

0.9311

CHISEL
(after correction)

0.9700

0.9359

Alleloscope

0.9671

0.9906

CHISEL
(before correction)

0.7858

0.9873

CHISEL
(after correction)

0.8404

0.9943
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P6461

Alleloscope

0.8638

0.9904

CHISEL
(before correction)

0.7932

0.9624

CHISEL
(after correction)

0.8143

0.9411

Alleloscope

0.9261

0.9905

CHISEL
(before correction)

0.9267

0.9383

CHISEL
(after correction)

0.9496

0.9446

Alleloscope

0.8249

0.9525

CHISEL
(before correction)

0.6515

0.6412

CHISEL
(after correction)

0.6533

0.6475

Benchmark with subsampling
50% subsample

25% subsample
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Supplementary Figures

Supplementary Figure 2.1: Demonstration of Alleloscope’s refinement step on two example
regions of P5931.
For chr2 and chr3 (each row) of P5931, the haplotype profiles of three scenarios are shown (each
column): (𝜌̂𝑖𝑟 , 𝜃̃𝑖𝑟 ) values with 𝜃̃𝑖𝑟 computed by plugging known SNP phases from matched linkedread sequencing data, colored by the inferred haplotype profile from the second-round estimation;
(𝜌̂𝑖𝑟 , 𝜃̂𝑖𝑟 ) values with 𝜃̂𝑖𝑟 originally estimated by Alleloscope; and (𝜌̂𝑖𝑟 , 𝜃̂ ′𝑖𝑟 ) values with 𝜃̂ ′𝑖𝑟
estimated by Alleloscope‘s refinement step. The colors and shapes represent different haplotype
profiles from the original and second-round estimation.
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Supplementary Figure 2.2: The estimated genome-wide haplotype profiles by Alleloscope
with (top) and without (bottom) known phases for the P5931 sample.
In the color legend, M and m represent the “Major haplotype” and “minor haplotype” respectively.
The cells in both plots are ordered by their ordering in the linked-read-based heatmap.
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Supplementary Figure 2.3: Supplementary Fig. 3: The estimated genome-wide haplotype
profiles by CHISEL with and without known phases for the P5931 sample under different
settings.
For each result (each row), CHISEL gives two heatmaps: the allele-specific copy number state (left),
and the major/minor haplotypes where there is an allelic imbalance (right). CHISEL includes an
additional “correction step”, in which the inferred clones are used to generate consensus allelespecific copy number profiles for all cells within each clone. (a) The result before correction
estimated using the default setting with the cell’s ordering from d. (b) The result after correction
estimated using the default setting with the cell’s ordering from d. (c) The result after correction
estimated using a block size=1 with the cell’s ordering from d. (d) The result by plugging in known
phases provided by the matched tumor linked-read sequencing with 1M block size. (e) The result
by plugging in known phases provided by the matched tumor linked-read sequencing with 50k block
size. (f) The result by plugging in known phases provided by the matched normal linked-read
sequencing with 1M block size.
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Supplementary Figure 2.4: Supplementary Fig. 4: Down-sampling results of both
Alleloscope and CHISEL on a high-coverage scDNA-seq dataset of a breast cancer sample
(section E).
The results on the original dataset (left), on the 50% subsampled dataset (middle) and on the 25%
subsampled dataset (right), given by Alleloscope (a) and CHISEL (b). For Alleloscope, M and m
represent the “Major haplotype” and “minor haplotype” respectively in the color legend. For CHISEL,
two heatmaps are given: the allele-specific copy number state (top), and the major/minor
haplotypes where there is an allelic imbalance (bottom). The corrected plots are shown here. The
cells in the plots of 50% and 25 subsampled datasets are ordered by their ordering in the linkedread-based heatmap respectively for the two methods.
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Supplementary Figure 2.5: Power for the detection of 1 copy deletion and 1 copy
amplification for data of varying coverage (per base), heterozygous SNP count, and number
of cells.
The heterozygous SNP count reflects the size of the region: larger regions contain more
heterozygous loci. Cells were clustered based on the minimum distance of 𝜃̂𝑖 to the canonical
values. Top: phasing accuracy, defined as the proportion of SNPs with 𝐼̂𝑗 correctly estimated;
bottom: cell CNV state accuracy, defined as the proportion of cells that are correctly assigned to
carrier state. Amp: amplification. Del: deletion. Line types represent different proportions (50%,
10% and 5%) of carrier cells. The number of SNPs, coverage, number of cells and purity were set
as 10,000, 0.03, 1000, and 0.5 if not specified.
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Supplementary Figure 2.6: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the P5846 sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.7: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the P5847 sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.8: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the P5915 sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.9: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b&c) for the P6198 sample.
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Two segmentation methods were applied on this sample. (b) The genome-wide haplotype profiles
estimated using FALCON. (c) The genome-wide haplotype profiles estimated using ASCAT. In the
color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.10: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the P6335 sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.11: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the P6461 sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.12: The segmentation plot and heatmap of the genome-wide
haplotype profiles for the breast cancer sample (section D).
(a) Genome segmentation using HMM on the pooled coverage signals across the cells. (b)
Genotype profiles of five example regions. The coloring scheme is same as that in part (c). (c)
Hierarchical clustering of single-cell ASCN genotypes reveals complex subclone structure.
Genotypes of the five regions in three example cells from the three major subclones are shown in
the left. Different colors represent different genotypes. In the color panel, M and m represent the
“Major haplotype” and “minor haplotype” respectively.
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Supplementary Figure 2.13: Phasing accuracy for the CNA regions in the P6198 sample by
comparing to the matched linked-read sequencing data.
LOH: segments with any LOH events. Amp: segments with amplifications that lead to allelic
imbalance. Ctrl: control segments without allelic imbalance. For the LOH (n=9), Amp (n=14), and
Ctrl (n=11) regions, the boxplots show the interquartile range and the median.
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Supplementary Figure 2.14: Genome-wide coverage comparison in large genomic bins
between two normal cell types for the SU008 sample.
Each point in the scatter plots represents the normalized read counts in each 10Mb bin along the
genome for endothelial cells (left) and fibroblasts (right). The normalized read counts were
computed by dividing the median read counts of cells of one normal cell type by the median read
counts of cells of the other cell type.
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Supplementary Figure 2.15: Single cell genotyping of CNV events by Alleloscope for
scATAC-seq data of a basal cell carcinoma sample (SU006).
(a) Genotype profiles of six example regions. The regions were taken from the segmentation of
whole exome sequencing (WES) data. Each dot represents a cell-specific (𝜌̂𝑖 , 𝜃̂𝑖 ) pair. Cells are
colored by annotation derived from peak signals [63]. Two tumor cell clusters, identified using ATAC
peaks, are labeled in red and blue; fibroblasts (Fibro) are labeled in grey. The density contours of
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the three cell subpopulations are also shown. (b) Hierarchical clustering of cells in scATAC-seq by
𝜃̂𝑖 reveals that the two tumor subpopulations are differentiated by peak signals that don’t correlate
with broad copy number events.
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Supplementary Figure 2.16: Confidence scores for the genotype assignment of each cell in
each region for the SNU601 scDNA-seq dataset.
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Supplementary Figure 2.17: Distribution of the posterior confidence scores of subclone
assignment for the 2,753 cells from SNU601 scATAC-seq.
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Supplementary Figure 2.18: The segmentation plot (a) and heatmap of the genome-wide
haplotype profiles (b) for the HM-SNS sample.
In the color panel, M and m represent the “Major haplotype” and “minor haplotype” respectively.
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Supplementary Tables

Supplementary Table 2.1: Summaries of the scDNA-seq datasets.
Sample
P5846
P5847
P5915
P5931
P6198
P6335
P6461
SNU601
BC10x
(secD)
BC10x
(secE)

Cancer
type
Gastric
Gastric
Colorectal
Gastric
Colorectal
Colorectal
Colorectal
Gastric
Breast
Breast

Source
Primary
tissue
Primary
tissue
Liver meta
Primary
tissue
Liver meta
Omentum
meta
Primary
tissue
Ascites
meta
Primary
tissue
Primary
tissue

MSI
status
MSS

Paired
normal
Yes

Linked
-reads
No

Coverage
per cell

Cell
number

Ref

454,806

510

[99]

-

Yes

No

422,134

715

-

MSS
MSI

Yes
Yes

Yes
Yes

1,262,629

233

[99]

730,932

796

-

MSS
MSS

Yes
No

Yes
Yes

532,343

2,271

[99]

564,058

953

[99]

-

Yes

Yes

483,524

1,242

-

MSS

No

No

565,648

1,531

[93]

-

No

No

781,506

1,916

[91]

-

No

No

951,225

2,053

[91]
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Supplementary Table 2.2: Performance of CHISEL with or without external phasing
information.
CHISEL was run with default setting (50kb block size with external phasing information) or without
external phasing (block size 1)
Dataset

Method

Sensitivity

Specificity

P5931

CHISEL: default
(before correction)

0.7520

0.9434

CHISEL: default
(after correction)

0.0112

0.9508

CHISEL: block size 1
(before correction)

0.5939

0.7878

CHISEL: block size 1
(after correction)

0.7465

0.7948

CHISEL: default
(before correction)

0.9397

0.9311

CHISEL: default
(after correction)

0.9700

0.9359

CHISEL: block size 1
(before correction)

0.8067

0.8608

CHISEL: block size 1
(after correction)

0.8320

0.8686

CHISEL: default
(before correction)

0.7858

0.9873

CHISEL: default
(after correction)

0.8404

0.9943

CHISEL: block size 1
(before correction)

0.6959

0.9705

CHISEL: block size 1
(after correction)

0.7450

0.9782

P6198

P6335
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Supplementary Table 2.3: Differentially accessible peaks of each subclone in SNU601.
The

full

supplementary

table

can

be

found

with

this

link:

https://static-content.springer.com/esm/art%3A10.1038%2Fs41587-021-00911-w/MediaObjects/4
1587_2021_911_MOESM3_ESM.xlsx

Supplementary Table 2.4: Summaries of the scATAC-seq datasets.
Sample
SU006
SU008
SNU601

Cancer type

Source

Basal
cell
carcinoma
Basal
cell
carcinoma
Gastric

Primary tissue

Matched
DNA
Bulk WES

Primary tissue

Bulk WES

Ascites meta

scDNA-seq

73

Coverage
per cell

Cell
number

Ref

41,368

2771

[63]

36,057

788

[63]

73,845

3614

-

Supplementary Results

Benchmark 1: Assessment of Alleloscope and CHISEL using whole genome haplotypes
derived from linked read sequencing
So far, CHISEL is the only other comparable method for allele-specific copy number estimation
with scDNA-seq data. We comprehensively benchmarked Alleloscope and CHISEL using the
following two strategies: (1) We compared each method’s output under default parameter settings,
without linked read phasing, to the same method’s output obtained given linked-reads phasing.
This was done for the five samples (P5931, P5915, P6198, P6335, and P6461) of varying
complexity for which matched linked-read sequencing was performed. (2) We compared each
method’s output at original sequencing coverage to the same method’s output at 50% or 25%
coverage. This was performed for the high-coverage breast cancer sample that CHISEL analyzed
in their paper. The rationale is that results at original coverage, though noisy, should be closer to
the truth than results at reduced coverage, and thus the method whose output remains more stable
under data down-sampling is more accurate at these lower coverages (Supplementary Methods).
For the first benchmark strategy, we used P5931 as an illustrating example. P5931 tumor sample
carries simpler but representative haplotype-specific profiles. For each method, we obtain two
different sets of results: Results obtained by default parameter settings, and results obtained by
plugging in known phases provided by the matched linked-read sequencing data. The latter, results
obtained using known phases, is used as the gold standard for assessing each method.
Supplementary Fig. 2 compares the estimated genome-wide haplotype profiles by Alleloscope with
and without known phases. As explained in the manuscript, Alleloscope’s color scheme gives a
different color for each allele-specific copy number state, with gray being normal diploid (“Mm”),
gradients of brown being amplification, and gradients of blue being deletion. Alleloscope achieved
a sensitivity of 0.9402 and specificity of 0.9986. The sensitivity here can also be referred to as
“recall.”
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For CHISEL, there is an extra “correction step” where the inferred clones are used to generate
consensus allele-specific copy number profiles for all cells within each clone. In Supplementary Fig
3, we show CHISEL’s output with and without this correction step. For each result, CHISEL gives
two heatmaps: the left heatmap showing the allele-specific copy number state, and the right
heatmap showing, for configurations where there is an allelic imbalance, which is the major allele.
Sensitivity for CHISEL is 0.7520 (before correction) and 0.0112 (after correction), and specificity is
0.9434 (before correction) and 0.9508 (after correction). As a sanity check, we also compared the
two “gold standards”: CHISEL’s results obtained using linked-reads phasing, and Alleloscope’s
results obtained using linked-reads phasing. The two gold standards have a similarity of 0.9945
(before correction) and 0.9851 (after correction), thus indicating that they are both accurate
reflections of the underlying truth.
Note that for this example, CHISEL’s clone-based correction step actually erases most of the signal
(the amplifications on chr7, chr8, and chr20, as well as the deletion on chr21 are erased by the
correction). However, in other samples, we have noticed the reverse, where the results after the
correction are better. Thus, CHISEL’s estimates are not robust to errors in clonal inference. The
better one of CHISEL’s two outputs (the uncorrected version) still has significantly lower specificity
and sensitivity as compared to Alleloscope.
Comparing Supplementary Figures 2 and 3, we can see how the results from Alleloscope and
CHISEL differ. The cells in both plots are ordered by their ordering in the linked-read-based
heatmap. In CHISEL’s results, the cells deemed noisy are labeled with a grey color in the clonal
assignment for each result. There are many more “horizontal stripes”, showing cells that have copy
number estimates that disagree with its clonal average. Also, there are many more cells deemed
“too noisy” by CHISEL, these are clustered at the tops and bottoms of the heatmaps. This leads to
the lowered specificity and sensitivity of CHISEL in this sample.
Besides using the default setting, we also explored the extent to which CHISEL relies on the
external phasing information. We found that CHISEL is very sensitive to not only the block-size
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parameter, but also the selection of the phasing panel using P5931 as an example (Supplementary
Fig. 3; Supplementary Table 2). Even for the same patient, the tumor tissue and matched normal
tissue differ in their phasing profiles at key regions surrounding chromosomal breakpoints, which
can lead to different results under CHISEL. Effects of external phasing were also explored in two
additional samples—P6335 and P6198 (Supplementary Table 2). This reinforces the rationale that,
for allele-specific copy number estimation of tumor samples, it would be best to not rely on external
phasing.
We also performed such detailed assessment between CHISEL and Alleloscope on four other
samples, with differing CNA complexity, that have matched linked-read sequencing data—P6198,
P6335, P5915 and P6461. Sensitivity and specificity of the four samples and those of P5931 for
the two methods are shown in Table 1. The results show that Alleloscope outperforms CHISEL in
allele-specific copy number estimation for most samples, and both methods perform similarly for
P6198. The high 0.97 sensitivity of CHISEL after correction results from the fact that P6198 is a
tumor sample with one major subclone and multiple LOH regions that are easier to be detected
(Supplementary Fig. 9). For P6198, CHISEL generates consensus allele-specific copy number
profiles for all cells clustered in the same clone, which leads to extremely high sensitivity in this
easier case.

Benchmark 2: Assessment of method robustness by downsampling
In addition to the linked-reads based benchmark, we also compared Alleloscope and CHISEL on
the breast cancer sample that CHISEL analyzed in their study. This data set does not have true
phasing information, but was sequenced at much higher coverage, and thus, we subsampled 50%
and 25 % of the original dataset and compared the estimated results of the subsampled datasets
to that of the original datasets to assess the performance of the two methods across varying
sequencing coverage. The results on the original dataset, on the 50% subsampled dataset and on
the 25% subsampled dataset, given by Alleloscope and CHISEL, are shown in Supplementary Fig.
4. For CHISEL, the clone-corrected output plots are shown since they are more accurate than the
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uncorrected ones. Using the results from the original dataset as the ground-truth, performance of
Alleloscope and CHISEL for the two subsampled datasets is shown in Table 1. Sensitivity and
specificity are both high (>0.90) for both Alleloscope and CHISEL on the 50% subsampled dataset.
However, for the 25% subsampled dataset, sensitivity decreases to ~0.82 and specificity decreases
to ~0.95 for Alleloscope, while CHISEL fails in estimating allele-specific copy numbers on this
dataset with both sensitivity and specificity decreasing to ~65%. The performance can also be
visualized in Supplementary Fig. 4. While the lineage plots look noisier with more dark horizontal
bands as the coverage decreases, CHISEL fails to not only estimate allele-specific copy numbers
for some regions (like those grey vertical bands on chr10, 11, 13, and 17), but also the direction of
the two haplotypes for almost the whole genome.
For scDNA-seq allele-specific copy number estimation, Alleloscope has higher sensitivity and
specificity compared to the known phases provided by the matched linked-reads on the five scDNAseq samples. The subsampling results also suggest that Alleloscope is more robust at lower
coverage.

Algorithmic differences between CHISEL and Alleloscope
Here we describe the algorithmic differences between CHISEL and Alleloscope, which can help
explain the differences in their performance. CHISEL was designed for scDNA-seq data and is not
applicable to scATAC-seq data. The improvements of Alleloscope over CHISEL are due to
fundamental differences in their algorithm design: Alleloscope is a top-down method that first
segments the genome, allowing for the aggregation across all SNPs in a large region to estimate
haplotype profiles for each cell. This allows the algorithm to achieve higher sensitivity for events
carried by smaller subclones, as well as robustness against local fluctuations in allelic coverage.
Delineating the segments in the first step also allows for the simultaneous estimation of phase and
single cell haplotype ratios, thus bypassing the need for external phasing data. In comparison,
CHISEL is a bottom-up approach that estimates copy number profiles of each cell in smaller fixedlength bins (default 5Mb). Selection of the bin size faces a trade-off between having more SNPs
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(and thus more data points for estimation) and heterogeneity of the true CNA profile. To overcome
the sparsity of data within each bin, CHISEL relies on external phasing to achieve better allelespecific copy number estimation. Choice of the external phasing data can substantially impact
estimation results (Supplementary Fig. 3).

Supplementary Methods

Second-stage estimation
To improve copy number state estimation in regions with a low proportion of cells carrying CNAs,
a second-stage scheme was developed. We first estimated cell-level CNV states by the methods
described in Methods. After the first-round estimation, some cells with low proportions might have
shifts in their coverage (𝜌̂𝑖𝑟 ) but their allelic imbalance level (𝜃̂𝑖𝑟 ) does not correspond to the
coverage change for some regions. Visualizing this from the scatter plots, the second-stage
estimation can be executed to estimate phases using only the targeted cells.
In the second-round estimation, SNPs in region 𝑟 are first filtered out if no read is observed among
the targeted cells. The phases of these filtered SNPs can be estimated as described in the “SNP
Phasing and Single-cell Allele Profile Estimation per region” section of Methods. Using the
estimated phases for the filtered SNPs, the allelic imbalance level of the targeted cells and other
non-targeted cells can both be estimated.

Benchmarks of Alleloscope and CHISEL
We benchmarked Alleloscope and CHISEL on the scDNA-seq samples using two strategies
explained below. These samples include five (P5931, P5915, P6198, P6335, and P6461) for which
matched linked-read sequencing was performed, and the high-coverage breast cancer sample that
CHISEL analyzed in their paper.
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For CHISEL, we prepared the four required input files following the online tutorial. Since no
matched normal sample exits for P6335 and BC10x, we first generated bam files for normal cells
in the tumor samples using CHISEL as they suggested. To run CHISEL with the default settings,
Eagle2 through Michigan Imputation Server was used to phase germline SNPs following their
pipeline.
Benchmark 1: Comparison to results obtained by linked-reads phase information.
For each method, we obtain two different sets of results: Results obtained by default parameter
settings, and results obtained by plugging in known phases provided by the matched linked-read
sequencing data. The latter, results obtained using known phases, is used as the gold standard for
assessing each method. Since linked-read sequencing data can provide phase information
covering the Mb scale, the haplotype block was set as 1Mb for P5931 to run CHISEL to retrieve
the result used as the gold standard. For P6198 and P6335, we observed that setting a block size
of 1Mb introduced additional noise because the 1Mb block used might be different from that
provided by the linked-read sequencing data. We instead used the original 50kb block for these
two samples. GRCh38 reference genome was used to analyze these samples. Between the results
by default setting and by plugging in known phases, the directions of the two haplotypes
(considered as either A or B) might be reversed for some chromosomes depending on the phasing
information used. To make the results comparable, directions of the two haplotypes estimated by
the default setting were used as the scaffold to place the directions of the two haplotypes for the
results by plugging the known phases, which was similar to the comparison in Alleloscope.
Benchmark 2: Comparison of results at down-sampled coverage to results at original coverage for
a high coverage sample.
We compared Alleloscope and CHISEL on the breast cancer sample that CHISEL analyzed in their
study by subsampling. We first subsampled 50% and 25 % of the original dataset using samtools.
Alleloscope and CHISEL were run on the original dataset, 50% and 25% subsampled datasets
using default settings on the GRCh37 reference genome. The estimated results of the subsampled
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datasets were compared to that of the original datasets (used as the gold standard) to assess the
performance of the two methods across varying sequencing coverage respectively.
To compare Alleloscope and CHISEL, each segment analyzed by Alleloscope was divided into
5Mb bins following the format in CHISEL’s output. Then, sensitivity and specificity were computed
as follows:

𝑆𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =

𝑇𝑃
,
𝑃

where:
TP 5Mb bins across the cells and across the genome considered to be abnormal
(haplotype profiles other than 1|1) in both the results used as the gold standard and the
estimated results;
P: 5Mb bins across the cells and across the genome considered to be abnormal in the
result used as the gold standard.
and
𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 = 𝑇𝑁/𝑁,
where
TN: 5Mb bins across the cells and across the genome considered to be normal diploid in
both the results used as the gold standard and the estimated results;
N: 5Mb bins across the cells and across the genome considered to be normal diploid in the
result used as the gold standard.
For a sanity check, the similarity was also computed for the two “gold standards”: CHISEL’s results
obtained using linked-reads phasing, and Alleloscope’s results obtained using linked-reads phasing.
We first generated two cell by 500M-bin matrices for both methods with the values indicating the
allele-specific copy number profiles. Then similarity was computed as the proportion of the same
copy number profiles across the cells and the 500M bins.
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Simulations and Power Analysis
For a simulated region, let 𝑛 be the number of cells, 𝑚 be the number of heterozygous SNPs, 𝜃 be
the major haplotype proportion, and 𝜇𝑖 be the total coverage of cell 𝑖 sampled from the cells on chr7
in the P5931 tumor sample. For cell 𝑖, we simulated total coverages of SNP j (𝜇𝑖𝑗 ) using a Poisson
distribution
𝜇𝑖𝑗 ~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜇𝑖 ),
where 𝑖 = 1~𝑛. Parallelly, phases of SNP j (𝐼𝑗 ) were simulated under a Bernoulli distribution
𝐼𝑗 ~𝐵𝑒𝑟𝑛𝑜𝑢𝑙𝑙𝑖(0.5),
where 𝐼𝑗 indicates whether a reference allele is on the major haplotype for SNP j, and 𝑗 = 1~𝑚.
Using 𝜇𝑖𝑗 and 𝐼𝑗 , read counts of reference alleles of SNP j in cell i (𝐴𝑖𝑗 ) were simulated under a
Binomial distribution
𝐴𝑖𝑗 ~𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝜇𝑖𝑗 , 𝑝𝑖𝑗 ),
where 𝑝𝑖𝑗 is the proportion of the reference allele for SNP 𝑗 in cell 𝑖 with the values shown in the
following table
𝑝𝑖𝑗

cell 𝑖 with CNA

cell 𝑖 without CNA

𝐼𝑗 = 1

𝜃

0.5

𝐼𝑗 = 0

1−𝜃

0.5

Then simulated read counts of alternative alleles of SNP 𝑗 in cell 𝑖 (𝐵𝑖𝑗 ) were computed by
𝐵𝑖𝑗 = 𝜇𝑖𝑗 − 𝐴𝑖𝑗
To explore the effects of SNP numbers, cell coverage, cell numbers, and purity, power analysis
was performed for one-copy deletion and one-copy amplification scenarios. We assessed the
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accuracy for phasing and cell-level CNA state estimation under the following scenarios: SNP
numbers from 1,000 to 50,000, mean coverage from 0.01 to 0,05 for each cell, and cell number
from 500 to 2500. For different scenarios, we assessed the effect of three purities: 0.5, 0.1, and
0.01, reflecting from larger subclones to rare subclones. Besides the parameters that were
assessed, other parameters were set as follows: the cell number 𝑛 = 1,000, the SNP number 𝑚 =
10,000, 𝜃 was set as 1 and 0.66 for cells carrying deletion and one-copy amplification respectively
with the purity equal to 0.5.
Phasing accuracy was calculated by comparing true 𝐼𝑗 ’s and estimated 𝐼̂𝑗’s in the region with the
details described in the previous section. On the other hand, the accuracy of cell CNA state
estimation was the clustering accuracy using the estimated 𝜃̂𝑖 values. Cells with 𝜃̂𝑖 values smaller
than the midpoints between true 𝜃 of normal cells (𝜃𝑜 = 0.5) and true 𝜃 of carriers (𝜃𝑑𝑒𝑙 = 1 ; 𝜃𝑎𝑚𝑝 =
0.66 ) were considered as normal cells; otherwise, cells were considered as carriers. The clustering
accuracy was calculated by comparing the clusters to the true cell states.

Assessment of coverage in large genomic bins for scATAC-seq
To compare with the CNA analysis method using only coverage for the scATAC-seq data, we
assessed if false-positive signals can still be observed even with large genomic bins using the two
normal cell types (endothelial cells and fibroblasts) in the SU008 scATAC-seq dataset. The identity
of the two normal cell types was based on their genome-wide peak signals. Following the method
in the original paper [63], we first summed all the read signals normalized with the cell size in each
10Mb bins with a 2Mb sliding window along the genome for each cell. Then for each normal cell
type, the signals of each bin were normalized by dividing the median of the total signals across the
cells in one normal cell type by the median of the total signals across the cells in the other cell type.
This step was similar to using normal cells as the control to normalize the signals in tumor cells to
assess the copy number change.

82

Inference of MLE estimates for the copy number adjustment model
For peak k, the binomial distribution with specific terms to adjust for copy numbers is used to model
the observed read counts:
𝑌𝑐𝑘 ∼ 𝐵𝑖𝑛𝑜𝑚𝑖𝑎𝑙(𝑁𝑐 , 𝑓𝑘 (𝜃𝑐 )𝑝𝑐𝑘 ),
see details of each term in Methods. For each peak 𝑘, two clones (clone 𝑐1 and clone 𝑐2 ) are
compared using the generalized likelihood ratio test (GLRT) with the hypothesis 𝐻0 : 𝑝𝑐1𝑘 = 𝑝𝑐2 𝑘 =
𝑝0 and 𝐻1 : 𝑝𝑐1 𝑘 ≠ 𝑝𝑐2 𝑘 . as the GLRT in this case has null distribution that is 𝜒12 , and has the form:
𝐿𝐿𝑅𝑘 = 2ℓ(𝑝̂ 𝑐1𝑘 , 𝑝̂𝑐2𝑘 ) − 2ℓ(𝑝̂ 0𝑘 )
Where

2ℓ(𝑝̂ 𝑐1𝑘 , 𝑝̂ 𝑐2𝑘 )

is

the

maximized
𝑝̂𝑐1,𝑘 =

log-likelihood

𝑌𝑐2 𝑘
,
𝑁𝑐2

𝑝̂ 𝑐1,𝑘 =

under

the

alternative,

with

𝑌𝑐2 𝑘
𝑁𝑐2

and 𝑙(𝑝̂0𝑘 ) is the maximized log-likelihood under the null, with the MLE computed as follows: For
simplicity, we first use 𝑝0 to denote 𝑝0𝑘 ; 𝑓1 , 𝑁1 , 𝑌1 to denote 𝑓𝑘 (𝜃𝑐1 ), 𝑁𝑐1 𝑘 , 𝑌𝑐1 𝑘 ; and 𝑓2 , 𝑁2 , 𝑌2 to denote
𝑓𝑘 (𝜃𝑐2 ), 𝑁𝑐2 𝑘 , 𝑌𝑐2 𝑘 . Then
ℓ(𝑝0 ) = log[( 𝑓1 𝑝0 )𝑌1 ( 1 − 𝑓1 𝑝0 )𝑁1−𝑌1 ( 𝑓2 𝑝0)𝑌2 ( 1 − 𝑓2 𝑝0 )𝑁2−𝑌2 ]
𝑑
𝑌1 𝑓1
𝑓1
𝑌2 𝑓2
𝑓2
ℓ(𝑝0 ) =
+ (𝑁1 − 𝑌1 ) (−
+ (𝑁2 − 𝑌2 ) (−
)+
)
𝑑(𝑝0 )
𝑓1 𝑝0
1 − 𝑓1 𝑝0
𝑓2 𝑝0
1 − 𝑓2 𝑝0
=

𝑌1
𝑓1
𝑌2
𝑓2
− (𝑁1 − 𝑌1 )
+ − (𝑁2 − 𝑌2 )
=0
𝑝0
1 − 𝑓1 𝑝0 𝑝0
1 − 𝑓2 𝑝0

𝑌1 (1 − 𝑓1 𝑝0 )(1 − 𝑓2 𝑝0 ) − 𝑝0 𝑓1 (𝑁1 − 𝑌1 )(1 − 𝑓2 𝑝0 ) + 𝑌2 (1 − 𝑓1 𝑝0 )(1 − 𝑓2 𝑝0 ) − 𝑝0 𝑓2 (𝑁2 − 𝑌2 )(1 − 𝑓1 𝑝0 )
= 0,
[𝑌1 𝑓1 𝑓2 𝑝0 2 − 𝑌1 (𝑓1 + 𝑓2 )𝑝0 + 𝑌1 ] − 𝑝0 𝑓1 𝑁1 + 𝑝0 𝑓1 𝑁1 𝑓2 𝑝0 + 𝑝0 𝑓1 𝑌1 − 𝑝0 𝑓1 𝑌1 𝑓2 𝑝 + [𝑌2 𝑓1 𝑓2 𝑝0 2
− 𝑌2 (𝑓1 + 𝑓2 )𝑝0 + 𝑌2 ] − 𝑝0 𝑓2 𝑁2 + 𝑝0 𝑓2 𝑁2 𝑓1 𝑝0 + 𝑝0 𝑓2 𝑌2 − 𝑝0 𝑓1 𝑌2 𝑓2 𝑝 = 0,
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(𝑌1 + 𝑌2 )𝑓1 𝑓2 𝑝0 2 − (𝑌1 + 𝑌2 )𝑝0 (𝑓1 + 𝑓2 ) + (𝑌1 + 𝑌2 ) − 𝑝0 𝑓1 (𝑁1 − 𝑌1 ) − 𝑝0 𝑓2 (𝑁2 − 𝑌2 )
+ 𝑝0 2 𝑓1 𝑓2 (𝑁1 − 𝑌1 ) + 𝑝0 𝑓2 (𝑁2 − 𝑌2 )
= 𝑓1 𝑓2 (𝑁1 + 𝑁2 )𝑝0 2 − (𝑓1 𝑁1 + 𝑓2 𝑁2 + 𝑓1 𝑌2 + 𝑓2 𝑌1 )𝑝0 + (𝑌1 + 𝑌2 ) = 0,
Let 𝑎 = 𝑓1 𝑓2 (𝑁1 + 𝑁2 ); 𝑏 = (𝑓1 𝑁1 + 𝑓2 𝑁2 + 𝑓1 𝑌2 + 𝑓2 𝑌1 ); 𝑐 = (𝑌1 + 𝑌2 ),

𝑝̂ 0 =

−𝑏 − √𝑏 2 − 4𝑎𝑐
1 1
, (0 < 𝑝0 < 𝑚𝑖𝑛 { , }).
2𝑎
𝑓1 𝑓2

Highly-multiplexed single-nucleus-sequencing (HM-SNS) data preprocessing and analysis
To show that Alleloscope can work on scDNA-seq data generated using protocols other than the
10x one, we applied the method to an HM-SNS dataset from Kim et al.’s study. Total 89 fastq files
for patient 2 were retried from SRP114962. Raw fastq files were aligned to the GRCh37 reference
genome using bwa-mem with duplicate reads removed using the Picard toolkits. SAMtools was
used to add read group, sort and index the bam files. After the bam files for individual cells were
generated, the standard GATK workflow was followed to joint-call SNPs for all the cells to generate
the SNP by cell matrices for the reference and alternative alleles. The bin-by-cell matrix was
generated using SCOPE [80]. To obtain an SNP set including only SNVs that are more possible to
be germline SNPs, we further filtered out the SNVs <10 reads or with extreme VAF values outside
the (0.3, 0.9) range. A 0.3 threshold was due to a small peak in the histogram of the VAF values
below 0.3, which resulted from many somatic SNVs detected when calling SNVs on individual cells.
Since no matched normal exists for this sample, we first identified tumor and normal cells in the
sample using 𝜃̂𝑖𝑟 estimated on each chromosome (instead of on the segments). Using total cell
sizes to retrieve the normalized 𝜌̂𝑖𝑟 values, we then estimated the allele-specific copy number
profiles using the same procedure described in the main text.
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3. CHAPTER 3 CANCER SUBCLONE DETECTION BASED ON DNA COPY NUMBER
IN SINGLE-CELL AND SPATIAL OMIC SEQUENCING DATA
Introduction
Cancer is a disease of intra-tissue clonal evolution, where DNA mutations combine with epigenetic
alterations to confer selective advantages on neoplastic cells, allowing them to proliferate, invade,
metastasize, and resist therapeutic treatment [4, 5]. Detection and characterization of genetically
different subclones is crucial for the study of cancer and for developing effective treatments and
prognostic strategies. Copy number alteration (CNA), one type of genomic variation, is a prevalent
manifestation of genome instability and a key driver of tumor evolution [29, 121, 122]. Subclones
distinguished by CNA have been successfully profiled using bulk and single-cell DNA sequencing
data [57, 58, 76, 95, 123-127]. CNA-based subclone detection in other types of single-cell omic
data, such as single-cell RNA sequencing (scRNA-seq) [75, 84-87] and single-cell transposaseaccessible chromatin-sequencing (scATAC-seq) [63, 64] further allows the joint analysis of genetic
mutations with gene expression and chromatin state. Recently, the maturation of spatial
transcriptomic (ST) technologies [68, 128] is heralding new opportunities for the study of spatial
subclonal dynamics through the mapping of DNA alterations of cells in situ [88, 89].
There is a need for reliable methods for CNA estimation and subclone detection for scRNA-seq,
scATAC-seq and ST data. Since these methods do not profile DNA, read coverage along the
chromosome is, at best, a noisy and indirect proxy of the underlying DNA copy number. Existing
methods for scRNA-seq data rely on smoothing across adjacent genes, e.g. inferCNV [75] and
CopyKAT [84]. Similar strategies were also used in CNA analysis for scATAC-seq data [63]. Other
methods such as HoneyBADGER [86] and CaSpER [85] consider allelic expression in their copy
number detection model, but the sparsity of allele-specific reads limits the improvement achieved
by these approaches. For spatial transcriptomics data, there is yet no vetted published method for
CNA-based subclone detection. STARCH, developed for CNA detection for ST data, leverages the
signals from nearby spots to overcome sparsity [88]. Since scRNA-seq and ST both measure gene
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expression, some emerging studies apply inferCNV, developed for scRNA-seq data, to analyze
CNA in tumor ST data [89].
The above methods partition cells/spots into clusters with distinct transcriptomic/epigenetic profiles,
but it is questionable to what degree the clusters represent subclones with distinct DNA-level copy
number profiles. Since broad megabase-level shifts in accessibility/transcription have been
observed between cell types, such methods can be prone to false-positive CNA detections. In
contrast, CONICS [87] profiles CNAs in scRNA-seq data with segmentation obtained from matched
bulk DNA-seq data to reduce false signals, but it was mainly developed for the full-length scRNAseq data and does not infer intratumor subclones, Like the above approaches, CONICS relies on
hierarchical clustering to cluster cells into subclones. Hierarchical clustering works when there are
clear, well-separated clusters in the data, and breaks down when the signal-to-noise ratio is low as
in the case of copy number estimates from scRNA-seq, scATAC-seq, and ST data. Hierarchical
clustering does not leverage the prior information in matched bulk DNA sequencing data, which is
often available, nor does it leverage the specific structure of subclonal copy number changes that
could be used to distinguish signal from noise.
We present Clonalscope, a method for CNA-based subclone detection that can be applied to
diverse single cell and spatial sequencing data types, such as scRNA-seq, scATAC-seq, and
spatial transcriptomics data. Clonalscope is based on nonparametric Bayesian clustering via a
novel nested Chinese restaurant process, which exploits the sparse nature of subclonal CNA
differences to identify de novo subclones with related, but distinct, copy number profiles.
Importantly, Clonalscope allows the leveraging of prior information from paired whole-genome or
whole-exome sequencing (WGS/WES) data to achieve more reliable subclone detection and
malignant cell labeling. When multiple samples are sequenced for a patient, Clonalscope also
allows the linking of subclones across samples to allow lineage tracing.
We first consider CNA estimation, malignant cell labeling and cancer subclone detection in scRNAseq data, where tissue-matched bulk and single-cell DNA sequencing data are used for
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benchmarking. We show that CNA estimates derived from scRNA-seq data alone, without
leveraging matched bulk DNA-seq data, can be inaccurate, and that the errors propagate
downstream to affect such common tasks as malignant cell identification. Leveraging WGS/WES
data, Clonalscope obtains precise copy number estimation and significantly improves the accuracy
of malignant cell labeling and subclone detection, as compared to existing approaches. Next, we
apply Clonalscope to scATAC-seq data from a gastric cancer cell line with matched scDNA-seq
data for validation, and show that Clonalscope can identify subclones based on allele-specific copy
number profiles. Finally, on ST data from breast, colorectal, and skin cancer, with expert pathology
annotation as validation, we show that Clonalscope successfully distinguishes malignant from nonmalignant cells and achieves reproducible spatial subclone mapping across adjacent tissue slices.

Results

Overview of the Clonalscope model and algorithm (Fig. 1)
Clonalscope starts by segmenting the genome into regions of homogeneous copy number states
in matched bulk whole-genome sequencing (WGS) or whole-exome sequencing (WES) data (Step.
1). Next, in single-cell RNA/ATAC sequencing (scRNA-seq/scATAC-seq) data, the relative
coverage fold change for each cell 𝑖 in each region 𝑟 is estimated under a Poisson model with the
baseline coverage computed from a set of pre-chosen diploid cells, such as immune cells (Step. 2;
Methods). This reduces the cell-by-gene matrix to a cell-by-region matrix, which serves as input to
the non-parametric Bayesian clustering model for subclone detection and subclonal copy number
inference (Step. 3). The non-parametric Bayesian clustering model is initialized to two clusters: a
cluster representing normal cells with fold change initialized to 1 across all regions, and a cluster
representing the major tumor clone with fold change in each region initialized to its fold change in
the matched bulk DNA sequencing (DNA-seq) data. Then, Clonalscope applies a nested Chinese
Restaurant Process to iteratively add/select copy number states for each genome segment, seed
new subclones, and assign each cell to a subclone. We use the term “nested” since the algorithm
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involves two Chinese Restaurant Processes: The first Chinese Restaurant Process samples
subclone membership and seeds new subclones, while for each new cancer subclone, the copy
number of each region is sampled via a second Chinese Restaurant Process. Clonalscope outputs
the estimated numbers of subclones, the copy number profiles for the subclones, and the subclone
assignment of each cell.
For spatial transcriptomics (ST) data, the same algorithm as described above applies, with “cell”
replaced by “spot”. We do not make use of the spatial coordinates in the clustering, and we don’t
smooth the cluster memberships across space. This is because we do not want to make a priori
assumptions on the degree of intermixing of subclones in space.
Clonalscope can also make use of allele-specific coverage, if such data is available. As above, we
start with a segmentation of the genome derived from bulk DNA-seq data, and then use Alleloscope
[76] to estimate both the relative fold change and allelic ratio for each cell 𝑖 in each region 𝑟. The
non-parametric Bayesian clustering then considers both relative fold change and allelic ratio in
computing the likelihood of a cell given a copy number profile. See Methods for details.

Subclone detection in scRNA-seq data validated by matched scDNA-seq data
Most existing copy number aberration (CNAs) estimation methods for scRNA-seq data do not allow
integration with bulk WGS data, and rely solely on a smoothing/averaging of the RNA expression
data for copy number estimation. Then, these methods usually apply hierarchical clustering on the
estimated single cell copy number profiles for subclone detection and or malignant cell labeling.
There can be considerable differences between RNA expression and DNA copy number [129],
even when the former is smoothed across large contiguous regions [130]. To examine how well
scRNA-seq data can recapitulate the underlying DNA-level heterogeneity, we consider scRNA-seq
data from three primary gastrointestinal cancer samples (P5847, P5931, and P8823) and one
colorectal metastasis (P6198). For P5847 and P5931, scDNA-seq data is available for validation,
and for P6198 and P8823, bulk DNA-seq is available and can be used to assess concordance of
mean copy number profiles. We benchmarked Clonalscope against inferCNV and CopyKAT, two

88

commonly used methods which do not use matched bulk DNA-seq data and simply apply
hierarchical clustering to detect subclones. First, we compared the correlations between mean copy
number estimates derived from epithelial cells in the scRNA-seq data with copy number estimates
derived from the matched DNA-seq data (Fig. 2a). All epithelial cells in the one metastasized tumor
are malignant cells. In the three primary tumors, most of the epithelial cells are expected to be
malignant though some normal epithelial cells might exist. Therefore, correlations between the CNA
profiles of epithelial cells in scRNA-seq data and that from the matched DNA-seq data are still
informative. Across the four samples (Supplementary Table 1), correlations of Clonoscope
estimates all exceed 0.7, existing methods which rely solely on scRNA-seq data are much lower,
close to 0.5. The detailed copy number estimates are shown in Supplementary Fig. 1. Across the
board, the lack of concordance between copy number estimates obtained by inferCNV and
CopyKAT and gold standard values derived from DNA-seq demonstrates the difficulty of copy
number estimation solely from RNA expression, and motivates the integration with matched bulk
DNA-seq for improved copy number-based subclone detection in scRNA-seq data.
In addition to providing the segmentation, the copy number profile from tissue-matched bulk DNAseq data is also informative for classification of scRNA-seq cells to malignant versus non-malignant
status, a pervasive analysis task in single cell cancer sequencing. Existing methods use
hierarchical clustering for this task, without utilizing the tissue-matched bulk DNA-seq data. We
consider P6198, the only metastasized tumor, where all epithelial cells should be malignant, for
benchmarking the accuracy of the malignant cell labeling. The results of malignant cell labeling by
Clonalscope (left), CopyKAT (middle) and hierarchical clustering (right) are shown in Fig. 2. By
utilizing the CNA profile from matched bulk DNA-seq data, Clonalscope’s accuracy in malignant
cell labeling reaches ~0.9986 accuracy. In comparison, CopyKAT which does not rely on matched
bulk DNA-seq data and which uses hierarchical clustering, has malignant cell labeling accuracy
~0.4529 on this sample (Supplementary Fig. 2). Even when the segmentation from matched bulk
DNA-seq data is used to delineate the regions, hierarchical clustering is still not able to reliably
label malignant cells (Supplementary Fig. 3). The results suggest malignant cell labeling can be
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improved by both leveraging copy number profiles from matched bulk DNA-seq data and by
applying a better clustering method designed for subclone detection.
Next, we compared the accuracy of subclone identification by Clonalscope, CopyKAT and inferCNV
for scRNA-seq data. Existing methods for copy number-based subclone detection for scRNA-seq
data have not explicitly evaluated the accuracy of intratumor subclones using the scDNA-seq gold
standard. Instead, benchmarking was only done at the bulk level. The comparison here was
performed on the P5931 primary gastric tumor sample since it has a clear subclonal structure from
scDNA-seq data (Fig. 2c left and [76]), and furthermore, it has matched normal scRNA-seq data
generated for benchmarking the performance of subclone identification (Supplementary Fig. 4).
Focusing on the malignant cells in the P5931 scRNA-seq dataset, the subclones identified from
Clonalscope (top), CopyKAT (middle), and inferCNV (bottom) were compared to the three main
subclones (D1 to D3) observed in matched scDNA-seq data (Fig. 2c-e; Methods). Proportions of
each subclone detected by each method are shown in Supplementary Fig. 5. Clonalscope
successfully identified all three major subclones with proportions comparable to those in scDNAseq data (Supplementary Fig. 5). Comparatively, subclone D3 was apparently missed in the results
of CopyKAT and inferCNV (Fig. 2d, e) It is worth noting that compared to CopyKAT, which by
default applies stringent filters to improve estimation, Clonalscope does not filter out as many cells
as CopyKAT in the estimation (Supplementary Fig. 5). With validation using scDNA-seq data, we
have shown that Clonalscope is able to reliably label malignant cells and detect intratumor
subclones by leveraging prior information from tissue-matched bulk DNA-seq data.

Subclone detection based on coverage and allelic ratio
Clonalscope can also utilize allele-specific information for subclone detection, when enough allelespecific reads can be extracted from single-cell sequencing data. We demonstrate this application
on scATAC-seq data for SNU601, a gastric cancer cell line with multiple subclones delineated by
scDNA-seq data. Some subclones in SNU601 are differentiated mostly by their allele-specific copy
number changes [76]. In our previous study [76],we applied a supervised classification approach

90

to assign each cell to one of the six major subclones detected in the matched scDNA-seq data. If
we were, instead, to perform unsupervised hierarchical clustering on the scATAC-seq data, we
would not be able to recapitulate the subclones due to the low signal-to-noise ratio (Supplementary
Fig. 6). The results for Clonoscope are shown in Fig. 3. Based on the segmentation of the pseudobulk (Fig. 3a), cells in the SNU601 scDNA-seq data can be clustered into six major subclones with
10 marker regions shown in Fig. 3b, which can be viewed as the ground truth for evaluating the
subclone detection results in the much shallower scATAC-seq data (Fig. 3c).
Since the six major subclones can be distinguished mainly based on 10 regions [76], we applied
Clonalscope on the 10 regions in scATAC-seq data to detect subclones. In SNU601 scATAC-seq
data, Clonalscope identified 13 subclones in an unsupervised manner (Fig. 3c). The leftmost
column shows the subclone identity of each cell assigned by Clonalscope (C). For comparison, we
also conducted supervised classification—simply assigning each cell in scATAC-seq into one of
the six subclones utilizing the subclonal copy number profiles from scDNA-seq data. The clusters
from supervised classification (S) are also shown in Fig. 3c. A detailed comparison of this
supervised subclone assignment versus Clonalscope unsupervised clustering is shown in the
contingency table in Supplementary Fig. 7. We see that the six major subclones (right) all have
counterparts in Clonalscope’s clusters that exhibited high enrichment. Specifically, the cells
assigned to S1 to S6 are mainly enriched in C10, C1, C5, C4, C12, and C3 respectively. The
consensus plot also shows comparable allele-specific copy number profiles between the mapped
clones from Clonalscope and those derived from the scDNA-seq data (Supplementary Fig. 8).
Additionally, we computed the UMAP coordinates for cells in the scATAC-seq data based on their
peak profiles and colored the cells based on their clonal assignment from Clonalscope and from
supervised classification (Supplementary Fig. 9; [76]). Clusters from the two methods show similar
local enrichment patterns on the UMAP plots. The example here indicates that Clonalscope can
detect subclones not only based on total coverage but also based on integrated modeling of total
coverage and allele-specific copy number profiles.
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Malignant spot labeling and subclone tracing on spatial transcriptomics data
We next demonstrate the application of Clonalscope on ST data. First, consider an ST data set
consisting of two adjacent slices from a squamous cell carcinoma (SCC) sample, with matched
bulk WES data. Leveraging the segmentation and bulk copy number profile from the matched WES
data (Fig. 4a), Clonalscope identified malignant cells in both slices, which are concentrated in space
despite the fact that Clonalscope did not make use of spatial coordinates in subclone detection (Fig.
4b). In this sample, no apparent subclones with distinguished copy number profiles were observed.
Clonalscope’s malignant spot labeling is highly concordant with expert pathology annotation (Fig.
4c). Further, across the two spatially adjacent slices, Clonalscope’s copy number estimates are
found to be highly correlated, with a correlation ~0.84 (Fig. 4d,e). These results demonstrate the
accuracy and reproducibility of the method. Detailed heatmaps are shown in Supplementary Fig.
10.
Currently, there is no method for reliably tracing subclones between samples collected at multiple
timepoints, anatomic positions, or spatial slices for the same patient, which is common in today’s
study designs. Since Clonalscope allows the flexible integration of prior information in subclone
detection, it can be applied to link subclones between samples for the same patient (Fig. 4f).
Subclone tracing by Clonalscope is demonstrated on an invasive ductal carcinoma data set with
samples from two tissue sections. Since there are no bulk DNA sequencing data available for these
samples, we simply segmented the genome by chromosome arm. First, we applied Clonalscope to
the ST data from one section, yielding a total of 15 clusters (Fig. 4g; left). As before, even though
spatial coordinates are not used in the clustering, the detected subclones are mostly spatially
contiguous. Next, these clusters were used as the prior clusters to initialize the subclone detection
for the second section, while allowing new clusters to be seeded and prior clusters to be
modified/removed (Fig. 4f). In the second section, 11 out of the 15 clusters were preserved with
one novel cluster detected (Fig. 4g; right). Comparing the spatial distributions of the detected
clusters in the two sections, we see that the sites of the corresponding clusters match well between
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the two slides. The localized subclonal signals from Clonalscope were also mostly concordant with
pathology annotation (Fig. 4h).

Clonalscope identified spatially segregated subclones expressing genes associated with
drug resistance and poor survival
We also applied Clonalscope on ST data from another IDC sample [68] with more detailed
characterization and analysis. In the ST data, Clonalscope identified nine clusters based on the
copy number profiles at the chromosome arm level (Supplementary Fig. 11). The nine clusters are
locally enriched in the tissue (Fig. 5a) although no spatial information was used in the estimation.
Among the clusters, cluster 2 is the major clone; cluster 3 and cluster 4 are the minor subclones
spatially segregated in the tissue. Most spots containing malignant cells are contained in cluster 2.
Comparatively, spots in cluster 3 are only limited to the connected blue region, while spots in cluster
4 are limited to three separate ducts in the right bottom region. The three clusters (cluster 2, 3, and
4) were separated due to differences in their copy number states for regions such as chr2q and
chr8q (Supplementary Fig. 11). To illustrate the difference in the copy number profiles between the
three clones, the mean fold changes across the spots for each of the three subclones are shown
in Fig. 5b. In the segmentation plot (Fig. 5b; bottom), the mean values of the three subclones are
close to each other in most regions. Four regions with significant shifts in the values of at least one
of the three subclones were highlighted in the density plots (Fig. 5b; top).
Next, we performed differential expression analysis on the three subclones detected by
Clonalscope. Gene expression of the top 6 highly expressed genes for subclone 3 and subclone 4
are shown in Fig. 5c and Fig. 5d respectively. The expression of these genes corresponds well to
the spatial distributions of the two subclones. These genes were also discovered to be associated
with outcomes of therapies and different adaptability of tumors. For example, FGG is highly
expressed in subclone 4. A previous study discovered that breast cancer patients with the
expression of this gene responded poorly to chemotherapy and had poor survival [131]. Another
example is the highly expressed IGFBP5 gene in subclone 3. This gene was found to be associated
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with metastatic phenotypes in breast tumors [132]. Higher expression of other genes in the two
subclones such as NNMT, TGM2, and CAPN13 were all shown to be associated with poor survival
and drug resistance in breast cancer patients [133-135]. The results suggest that the subclones
detected by Clonalscope can potentially be the sources of resistance to drugs and therapy.

Discussion
With the development of different single-cell sequencing technologies, a few methods have been
developed to detect subclones based on CNAs. So far, most current copy number detection
methods implement hierarchical clustering to detect subclones. Most of these methods do not
leverage information from matched DNA-seq data, and some of them require specifying the number
of subclones. Here we presented Clonalscope, a subclone detection method for single-cell and ST
data that leverages prior information from matched bulk DNA-seq data for malignant cell/spot
labeling and subclone tracing between related datasets. We demonstrated Clonalscope on diverse
single-cell data types including scRNA-seq, scATAC-seq, and spatial transcriptomics data.
We performed thorough benchmarks with matched scDNA-seq data and adjacent slides. Subclone
detection in scRNA-seq and scATAC-seq data were benchmarked with matched bulk and single
cell DNA-seq data. Compared to existing methods, Clonalscope obtains better copy number
estimates and malignant cell labels by leveraging the copy number profile from matched DNA-seq
data. Compared to other hierarchical clustering-based methods, Clonalscope also performs better
in subclone detection since it clusters the cells by mimicking the tumor evolutionary process. In
spatial transcriptomics data, we demonstrated that Clonalscope was able to accurately label
malignant spots with expert pathology annotation, and the reproducibility of spatial subclone
mapping of Clonalscope was shown by comparing two adjacent tissue slices.
Clonalscope can be applied to estimate copy number states and detect subclones on different
single-cell and spatial tumor sequencing data. Clonalscope estimates copy number states by
normalizing to a set of diploid cells for single-cell sequencing data. The diploid cells can be easily
annotated with marker genes in standard single-cell data analysis pipelines. Alternatively,
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Clonalscope can first normalize with the median profile across all cells in the dataset, and adjust
the selection of diploid cells based on the CNA profile of bulk DNA-seq data. For ST datasets,
diploid spots can be selected based on gene markers for different cell types, similar to that for
scRNA-seq data. Since H&E images are also provided for the ST data, expert pathology annotation
is also informative in selecting spots that mainly consist of diploid cells.
Clonalscope implements a nested Chinese Restaurant Process which mimics the tumor
evolutionary process to detect subclones. Within a tumor, CNAs that occur at the early
developmental stage are present in most malignant cells, while some subclonal CNAs are only
observed in a subset of malignant cells. The nested Chinese Restaurant Process not only samples
subclonal membership, but also samples copy number states for each region to create a new copy
number profile for the membership assignment. In sampling copy number states, most regions
retain the states as the existing ones, while there is a rare chance that an individual region obtains
a novel state, which is similar to the occurrence of a random mutation. The raw outputs from the
nested Chinese Restaurant Process depend on the scalar parameters. To retrieve more stable
estimation, we include a post-processing step in the pipeline to constrain the detected clusters with
at least 𝑛𝑚𝑖𝑛 of cells.
In the study, Clonalscope successfully performed non-parametric clustering to detect subclones on
scATAC-seq data. Comparatively, most scRNA-seq protocols only sequence the 3’ or 5’ end of
transcripts, limiting allele-specific CNA detection in scRNA-seq data. Recent technologies for
single-cell multi-modal sequencing provide opportunities for broader applications of the method in
the analysis of allele-specific CNA profiles. On the ST dataset from an IDC sample, we performed
detailed analysis and identified minor subclones that might resist to drugs. In addition to the
subclones, we also identify clusters consisting of spots with mixtures of tumor and stromal cells.
These spots can be the regions of interest for characterizing the interactions between tumor and
stromal cells. Another unique feature of Clonalscope is its ability to trace subclones, a common
task in studies where multiple tissue samples are sequenced for the same patient. In this paper,
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we demonstrated subclone tracing between different tissue slices from the same patient.
Clonalscope can also be used to link subclones between samples from different time points or
different anatomic positions. Tracing subclones for sequential time points will enable us to study
the dynamics between subclones. If the time-series data are from samples before and after
treatment, we will be able to identify minor subclones resistant to therapies. This feature broadens
Clonalscope’s applications to different types of tumors.

Materials and Methods

Datasets and pre-processing
The four 10x scRNA-seq datasets, five Visium spatial transcriptomics (ST) datasets, and the
SNU601 scATAC-seq dataset analyzed in this study are summarized in Supplementary Table 3.1.
P5847 and P8823 scRNA-seq data were generated using the protocol described in the previous
study [136]. The scRNA-seq datasets for P5931 and P6198 were retrieved from [136] and [137]
respectively.

The

Cell

Ranger

v

3.0

(https://support.10xgenomics.com/single-cell-gene-

expression/software/overview/welcome) was used to generate gene-by-cell matrices of unique
molecular identifier (UMI) counts for scRNA-seq data by aligning to the GRCh38 reference genome.
The ST datasets of the two replicates from squamous cell carcinoma (SCC) were provided by Ji et
al [68]. The three ST datasets from invasive ductal carcinoma (IDC) were retrieved from the 10x
website (https://www.10xgenomics.com/resources/datasets). The SNU601 scATAC-seq dataset
was retrieved from our earlier Alleloscope paper [76].

Single-cell and bulk DNA sequencing and data preprocessing
Results of segmentation and subclone detection of the four 10x scRNA-seq datasets were validated
with matched scDNA-seq and WGS data (Supplementary Table 3.2). The scDNA-seq data of
P5847 and P5931 were retrieved from [76], and P6198 was retrieved from [137]. WGS was
performed on the P8823 sample for this study.
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For WGS sequencing, DNA was first extracted using PureLink™ Genomic DNA Mini Kit as per the
manufacturer’s protocols. Genomic DNA was quantified using the Qubit 2.0 Fluorometer
(ThermoFisher Scientific, Waltham, MA, USA). For library preparation, NEBNext® Ultra™ DNA
Library Prep Kit for Illumina, clustering, and sequencing reagents was used throughout the process
following the manufacturer’s recommendations. Briefly, the genomic DNA was fragmented by
acoustic shearing with a Covaris S220 instrument. Fragmented DNA was cleaned up and end
repaired. Adapters were ligated after adenylation of the 3’ends followed by enrichment by limited
cycle PCR. DNA libraries were validated using a High Sensitivity D1000 ScreenTape on the Agilent
TapeStation (Agilent Technologies, Palo Alto, CA, USA), and were quantified using Qubit 2.0
Fluorometer. The DNA libraries were also quantified by real-time PCR (Applied Biosystems,
Carlsbad, CA, USA). Then the sequencing library was clustered onto a flowcell. After clustering,
the flowcell was loaded onto the Illumina HiSeq or equivalent instrument according to the
manufacturer’s instructions. The samples were sequenced using a 2x150bp Paired-End (PE)
configuration. Image analysis and base calling were conducted by the HiSeq Control Software
(HCS). Raw sequence data (.bcl files) generated from the Illumina machine was converted into
fastq files and de-multiplexed using Illumina bcl2fastq 2.17 software. One mismatch was allowed
for index sequence identification.

Segmentation on matched bulk DNA-seq data
The first step of Clonalscope is segmenting the genome into regions with different CNA profiles. In
this step, matched bulk DNA sequencing data (WGS/WES) or pseudo-bulk data from scDNA-seq
data can be segmented by an HMM-based segmentation method. The HMM method operates on
the binned counts of pooled cells, and assumes a Markov transition matrix on four hidden states
representing deletion, copy-neutral state, single-copy amplification and double-copy amplification:
1 − 3𝑡
𝑡
(
𝑡
𝑡

𝑡
1 − 3𝑡
𝑡
𝑡

𝑡
𝑡
1 − 3𝑡
𝑡

𝑡
𝑡
), where 𝑡 = 1 × 10−6 by default. Emission probabilities follow a
𝑡
1 − 3𝑡

normal distribution with 0.2 standard deviation with means depending on individual datasets. The
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segmentation was performed on pseudo-bulk scDNA-seq data for P5847, P5931, and P6198; WGS
data for P8823; and WES for SCC P6. Without matched bulk DNA-seq data, the segmentation was
performed on chromosome arms.

Selection of diploid cells
To identify diploid cells in the scRNA-seq data, the raw scRNA-seq UMI count matrices were first
filtered to include cells with at least 500 UMIs, at least 300 genes expressed, and at most 20% of
the reads mapped to mitochondria transcriptome. Next, the matrices were normalized with size
factors [138] and log-transformed. Then PCA was performed, and 30 PCs were selected for
clustering and UMAP analysis [139]. For separate clusters on the UMAP, we annotate the cell types
in the gastrointestinal tumor tissues using the marker genes from the previous study [136]. To
confidently differentiate malignant cells from normal epithelial cells in the P5931 scRNA-seq
dataset, we processed both tumor and normal scRNA-seq datasets together using the same
pipeline described above, and successfully labeled normal epithelial cells in the tumor dataset in a
separate cluster mainly containing cells in the normal dataset (Supplementary Fig. 4).
To identify reference cells in the Visium ST datasets, we first ran the Seurat (4.0.1) [140] pipeline
like that for scRNA-seq data to retrieve some preliminary clusters at the spot level. Since the
resolution of the Visium datasets are 1-10 cells, gradient expression of marker genes is observed
across the spots. However, we could still select a cluster with the least expression of the genes in
cancer cells (eg. ERBB2 for breast cancer cells) and high expression of other marker genes for
diploid cells. With the help of H&E images, we could also more confidently select the clusters
located in the regions mainly consisting of diploid cells.

Computing coverage change
With each region 𝑟 identified from matched DNA-seq data, we applied a Poisson model to reduce
a gene-by-cell matrix to a region-by-cell matrix for scRNA-seq data. For cell 𝑖 and gene 𝑔, we
defined the raw UMI count matrix as 𝑁𝑖𝑔 with
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𝑁𝑖𝑔 ~𝑃𝑜𝑖𝑠𝑠𝑜𝑛(𝜆𝑖𝑔 = 𝑠𝑖 𝑏𝑔 𝑋𝑖𝑟 );
, where 𝑠𝑖 is the normalizing factor of cell 𝑖; 𝑏𝑔 is the baseline expression of gene 𝑔; and 𝑋𝑖𝑟 is the
relative fold change of region 𝑟 for cell 𝑖. The normalizing factor 𝑠𝑖 is computed as follows:

𝑠𝑖 =

∑𝑔 𝑁𝑖𝑔
𝑚𝑒𝑑𝑖𝑎𝑛𝑖 (∑𝑔 𝑁𝑖𝑔 )

With a set of control cells 𝑐 = 1~𝑛𝑐 being defined, 𝑋𝑖𝑟 ′𝑠 of these cells are equal to 1. Therefore, 𝑏𝑔
can be estimated by solving
𝑛𝑐

𝑏̂𝑔 = 𝑎𝑟𝑔𝑚𝑎𝑥𝑏𝑔 (− ∑(𝑠𝑐 𝑏𝑔 − 𝑁𝑐𝑔 log(𝑠𝑐 𝑏𝑔 )))
𝑐=1

By derivation, 𝑏̂𝑔 can be solved with direct computation.
𝑏̂𝑔 = (

∑𝑐 𝑁𝑐𝑔
)
∑𝑐 𝑠𝑐

Then for each cell 𝑖 and region 𝑟,

𝑋̂𝑖𝑟 = 𝑎𝑟𝑔𝑚𝑎𝑥𝑥𝑖𝑟 (− ∑ (𝑠𝑖 𝑏̂𝑔 𝑋𝑖𝑟 − Nig log(𝑠𝑖 𝑏̂𝑔 𝑋𝑖𝑟 )))
𝑔∈𝑟(𝑔)

, where 𝑟(𝑔) is region 𝑟 which gene 𝑔 belongs to.
By derivation, 𝑋̂𝑖𝑟 can be solved with direct computation.
𝑋̂𝑖𝑟 = (

∑𝑔 𝑁𝑖𝑔
)
𝑠𝑖 ∑𝑔 𝑏̂𝑔

For ST datasets, the model is the same, but 𝑖 is the indicator for a spot instead of a cell.
In the real estimation, we excluded the cycle genes, HLA genes and the mitochondria genes
learning from CopyKAT [84]. We also filtered out the extremely variable genes and regions
overlapping <150 genes.
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Subclone detection with nested Chinese Restaurant Process
After the relative fold changes for each cell and each region (𝑋̂𝑖𝑟 ) are retrieved, A nested Chinese
Restaurant Process was applied to detect subclones in scRNA-seq data in a non-parametric
manner. First, we consider the coverage-only mode. The model for 𝑋𝑖𝑟 is
𝑋𝑖𝑟 ~𝑁(𝜃𝑖𝑟 , 𝜎𝑟2 )
𝜃𝑖𝑟 = 𝜇𝑍𝑖,𝑟
, with 𝑧𝑖 ∈ {1, … , 𝐾} is subclone 𝑘 which cell 𝑖 is assigned to. 𝜇𝑘𝑟 is the relative fold change of
subclone 𝑘 in region 𝑟, and 𝜎𝑟 is the standard deviation of region 𝑟. The targeted outputs of the
nested Chinese Restaurant Process are 𝑍𝑖 , the estimated subclonal identity of cell 𝑖; and 𝑈𝑘𝑟, the
copy number states of region 𝑟 for subclone 𝑘.
To include the prior information from the matched bulk DNA-seq data, we first set the prior 𝑈𝑝𝑟𝑖𝑜𝑟
as two clusters
𝜇11
𝑈𝑝𝑟𝑖𝑜𝑟 = [𝜇
21

…
…

𝜇1𝑅
0.5; 𝑑𝑒𝑙𝑒𝑡𝑖𝑜𝑛
𝜇2𝑅 ] | 𝜇1𝑟 = 1; 𝜇2𝑟 = {1.5; 𝑎𝑚𝑝𝑙𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛

, with 𝜇2𝑟 known from the DNA-seq data. Then for each cell 𝑖 = 1~𝑁,
1; 𝑖𝑓 𝑃(𝑋𝑖 |𝜇1⋅ ) > 𝑃(𝑋𝑖 |𝜇2⋅ )
𝑍𝑝𝑟𝑖𝑜𝑟 = [𝑧𝑝𝑟𝑖𝑜𝑟,1 , … , 𝑧𝑝𝑟𝑖𝑜𝑟,𝑖 , … , 𝑧𝑝𝑟𝑖𝑜𝑟,𝑁 ] ; 𝑧̂𝑝𝑟𝑖𝑜𝑟,𝑖 = {
2; 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
In the 𝑡 𝑡ℎ iteration of the nested Chinese Restaurant Process, we first iterate over all cell 𝑖. To
assign cell 𝑖 into one of the existing clusters, the probability of
\𝑖

𝜃̃𝑖 | 𝜃̃−𝑖 , 𝑋𝑖 =

𝜇̃𝑘𝑡 , 𝑝𝑖,𝑘𝑡 = 𝑃(𝑋𝑖 |𝜇̃𝑘𝑡 ) ×
{

𝑛𝑘 𝑡
𝑁 −1+𝛽

𝑛𝑒𝑤
𝑛𝑒𝑤
𝑛𝑒𝑤
)×
𝜇̃𝑖𝑡
, 𝑝𝑖𝑡
= 𝑃(𝑋𝑖 |𝜇̃𝑖𝑡

; 𝑘𝑡 = 1, … , 𝐾𝑡

𝛽
𝑁 −1+𝛽

, where 𝜃̃𝑖 | 𝜃̃−𝑖 , 𝑋𝑖 is the variable for the estimated mean of relative fold change for cell 𝑖 across all
\𝑖

the regions, conditioning on all other cells and the observation. 𝑛𝑘𝑡 is the number of cells assigned
to cluster 𝑘 from the 𝑡 𝑡ℎ iteration excluding cell 𝑖; and 𝑁 is the total number of cells. 𝛽 is the scalar
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parameter controlling the chance of accepting a new cluster in the process. 𝛽 was by default set
as 2. 𝜇̃𝑘𝑡 is the relative fold change across all regions for subclone 𝑘 from the 𝑡 𝑡ℎ iteration, and
𝑛𝑒𝑤
𝑝𝑖,𝑘𝑡 is the probability of cell 𝑖 being assigned to the 𝑘𝑡 cluster. 𝜇̃𝑖𝑡
is the relative fold changes
𝑛𝑒𝑤
across all regions for a newly seeded cluster for cell 𝑖 in iteration 𝑡 with the probability being 𝑝𝑖𝑡
.
𝑛𝑒𝑤
𝑝𝑖,𝑘𝑡 and 𝑝𝑖𝑡
can be calculated as follows

\𝑖

log 𝑝𝑖,𝑘𝑡 ~ ∑ log 𝑃(𝑋𝑖𝑟 |𝜇̃𝑘𝑡𝑟 ) + log(𝑛𝑘𝑡 )
𝑟

𝑛𝑒𝑤
𝑛𝑒𝑤
) + log(𝛽)
log 𝑝𝑖𝑡
~ ∑ log 𝑃(𝑋𝑖𝑟 |𝜇̃𝑖𝑡𝑟
𝑟

𝑛𝑒𝑤
To create 𝜇̃𝑖𝑡
, the second Chinese Restaurant Process was executed to select one of the existing

copy number states or seed a new copy number state for each region. We skip the subscript “it” for
the following notation. For each region 𝑟,

𝜇̃𝑟𝑛𝑒𝑤

𝑛 𝑘𝑡
𝑁−1+𝛼
={
𝛼
𝑛𝑒𝑤
𝜇𝑟 𝑙; 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦
𝑁−1+𝛼
𝜇𝑟𝑘 ; 𝑤𝑖𝑡ℎ 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦

𝜇𝑟𝑛𝑒𝑤 ~Unif(0,3)
, where 𝜇𝑟𝑛𝑒𝑤 is a newly seeded copy number state for region 𝑟. 𝑛𝑘𝑡 is the number of cells assigned
to cluster 𝑘 from the 𝑡 𝑡ℎ iteration. 𝛼 is the scalar parameter controlling the chance of accepting a
′
𝑛𝑒𝑤
new cluster in the process. By default, 𝛼 is set as 2. With 𝑝𝑖,𝑘
𝑠 for all 𝑘𝑡 clusters and 𝑝𝑖𝑡
being
𝑡

calculated, 𝑧̃𝑖𝑡 is sampled based on the probability.
After 𝑧̃𝑖𝑡 ’s are updated for all cell 𝑖, 𝜇𝑘𝑟 is sampled based on the following distribution
𝜇𝑘𝑟𝑡 |𝑒. 𝑒~𝑁(𝑋̅𝑘𝑟 ,

2
𝜎𝑟(𝑡−1)

𝑛𝑘 𝑡

)

, where 𝜎𝑟(𝑡−1) is the standard deviation of region 𝑟 for the (𝑡 − 1)𝑡ℎ iteration. Then 𝜎𝑟𝑡 can be
updated by computing
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1
2
𝜎𝑟𝑡 = √ ∑ (𝑋𝑖𝑟 − 𝜇𝑍𝑖 𝑟𝑡 )
𝑁
𝑖

For subclone detection with both coverage and allelic ratio, the model for 𝑋𝑖𝑟 is
𝑋𝑖𝑟 = [𝑃𝑖𝑟 , 𝛩𝑖𝑟 ]
𝛲𝑖𝑟 ~𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝑧𝑖𝑟𝜌 , 𝜎𝑟𝜌 )
𝛩𝑖𝑟 ~𝑁𝑜𝑟𝑚𝑎𝑙(𝜇𝑧𝑖𝑟𝜃 , 𝜎𝑟𝜃 )
In the formula, 𝛲𝑖𝑟 and 𝛩𝑖𝑟 are the estimated coverage and major haplotype proportion [76] for
region 𝑟 in cell 𝑖. 𝑧𝑖 ∈ {1, … , 𝐾} is subclone 𝑘 which cell 𝑖 is assigned to, and 𝜇𝑘𝑟𝜌 and 𝜇𝑘𝑟𝜃 are the
relative fold change and major haplotype proportion of subclone 𝑘 in region 𝑟 respectively. 𝜎𝑟𝜌 and
𝜎𝑟𝜃 are the standard deviations of relative fold change and major haplotype proportion for region 𝑟.
The nested Chinese Restaurant Process is similar to that used in the coverage-only mode. The
outputs from the estimation are 𝑍𝑖 , the estimated subclonal identity of cell 𝑖; and [𝑈𝑘𝑟𝜌 , 𝑈𝑘𝑟𝜃 ] the
allele-specific copy number states of subclone 𝑘 for region 𝑟.
The two parameters 𝛼 and 𝛽 control the numbers of subclones detected from the nested Chinese
Restaurant Process. To retrieve more stable estimation, the first few iterations of the raw outputs
from the nested Chinese Restaurant Process are trimmed. By default, 200 iterations are run and
the estimates from the first 100 iterations are trimmed. After the trimming step, each cell is assigned
to the most possible subclone 𝑘 using the majority vote strategy. Next, only the subclones with >
𝑛𝑚𝑖𝑛 cells assigned are kept, and the smaller subclones are removed. By default, 𝑛𝑚𝑖𝑛 is set as 1%
of cells. Then the cells originally assigned to the removed subclones are re-assigned to the existing
subclones. Then 𝑈𝑘𝑟 the copy number states of region 𝑟 for subclone 𝑘 is updated based on the
re-assignment.
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Assessing segmentation on scRNA-seq data and on matched DNA-seq data
To evaluate different segmentation methods on scRNA-seq data, we calculated the correlations
between the mean copy number profiles in scRNA-seq data to those from (pseudo)bulk DNA-seq
data. Three segmentation methods for scRNA-seq data were compared—segmentation from
matched bulk DNA-seq data; segmentation from CopyKAT and segmentation from inferCNV.
CopyKAT and inferCNV were run using the default parameters. CopyKAT and inferCNV perform
segmentation mainly at the gene level, and they output the estimated copy number profiles for each
gene in each cell. Therefore, we computed the mean copy number profiles across all epithelial cells
for each gene. Since the output values for CopyKAT are at the log scale, the values were
exponentially transformed to original values. Comparatively, we used Clonalscope to perform
segmentation on matched DNA-seq data and compute the mean fold changes for each segment
in scRNA-seq data. For easier comparison with CopyKAT and inferCNV, the mean fold changes
for each segment were transformed to the gene level.
All

scDNA-seq

data

were

pre-processed

with

the

Cell

Ranger

DNA

pipeline

(https://support.10xgenomics.com/single-cell-dna/software/overview/welcome, beta v.6002.16.0).
For P5847 and P5931, we applied Alleloscope [76] on the scDNA-seq data, and computed the
mean coverage changes across all identified malignant cells for each segment to retrieve the mean
copy number profiles for the pseudo-bulk DNA-seq data. For P6198, we generated the pseudobulk sample from the scDNA-seq data, and computed the mean coverage changes for each
segment. For P8823, we first quantified the reads in each window with a 100000 bp size for both
matched tumor and normal WGS data by running the “intersect” command in the bedtools [141].
The profile of the mean coverage changes for P8823 bulk DNA-seq data was then computed for
each segment by normalizing with the matched normal WGS data. Similarly, we also transformed
the vector of the mean coverage changes for all DNA-seq data from the segment scale to the gene
scale.
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Malignant cell/spot labeling on scRNA-seq and spatial transcriptomics data
Copy number profiles from matched bulk DNA-seq data can also be used to reliably detect
malignant cells/spots in scRNA-seq and ST datasets. After the subclones are detected in the
scRNA-seq and ST datasets, 𝜇̂ 𝑘 , the estimated copy number profiles of subclone 𝑘 can be
compared to the copy number profiles from matched DNA-seq data (𝜇1 ) across all regions. To
determine subclone 𝑘 is malignant or not, the revised cosine similarity (𝑆𝑐 ) was computed as
𝑆𝑐 =

∑𝑟[(𝜇̂ 𝑘𝑟 − 1) ⋅ (𝜇1𝑟 − 1)]
√∑𝑟(𝜇̂ 𝑘𝑟 − 1)2 √∑𝑟(𝜇1𝑟 − 1)2

If 𝑆𝑐 > 𝑆𝑚𝑖𝑛 (0.5 by default), the subclone 𝑘 is labeled as malignant.
The accuracy of malignant cell labeling was compared between Clonalscope, CopyKAT, and
hierarchical clustering on an scRNA-seq dataset. Clonalscope and CopyKAT were run using default
parameters. For hierarchical clustering, we first retrieved segments from matched DNA-seq data,
and estimated relative coverage fold changes for each cell in each segment using the function of
Clonalscope. Then hierarchical clustering was applied to cluster the cells based on the estimated
copy number profiles instead of using the Bayesian non-parametric clustering in Clonalscope.

Comparison of subclones between scRNA-seq data and matched scDNA-seq data
On the malignant cells identified in the P5931 scRNA-seq data, we compared the subclones
detected by Clonalscope, inferCNV, and copyKAT to those in the matched scDNA-seq data. In the
scDNA-seq data of P5931, 3 major subclones (D1~D3) were observed, which can be used as the
ground truth of the sample. Since we knew for P5931, CNAs are mainly on the four chromosomes
from the matched pseudo-bulk DNA-seq data, Clonalscope was run on the four chromosomes to
detect subclones with default parameters. For CopyKAT and inferCNV, hierarchical clustering
requires specifying the number of subclones. Since 6 and 5 subclones were used in the
segmentation for CopyKAT and inferCNV, we set the output numbers of subclones as 6 and 5
respectively.
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After the subclones in scRNA-seq data were detected from the three methods, we mapped the
subclones to the corresponding “true” subclones observed in the matched scDNA-seq data. For
subclone mapping, the revised cosine similarity (𝑆𝑐 ) was computed:

𝑆𝑐 =

∑𝑔[(𝜇̂ 𝑐𝑔 − 1) ⋅ (𝜇̂ 𝑑𝑔 − 1)]
2

√∑𝑔(𝜇̂ 𝑐𝑔 − 1) √∑𝑔(𝜇̂ 𝑑𝑔 − 1)

2

, where 𝜇̂ 𝑐𝑔 and 𝜇̂ 𝑑𝑔 are the mean fold change for gene 𝑔 across the cells assigned to subclone 𝑐
in scRNA-seq data and subclone 𝑑 ∈ [𝐷1, 𝐷2, 𝐷3] in scDNA-seq data. Subclone 𝑐 in scRNA-seq
data was mapped to the subclone 𝑑 with the highest similarity score. For Clonalscope, we summed
over all the region 𝑟 instead of gene 𝑔.

Subclone detection in scATAC-seq data
Following the pipeline described in our previous study [76], we processed the SNU601 scATACseq data and generated the region-by-cell matrices for relative fold changes and allelic ratios. Next,
we constrained the values for the relative fold changes to be < 3, and the values for the allelic ratios
> 0.05 and < 0.95 for more stable estimation. In our previous study, six major subclones were
detected in the SNU601 sample with differences in their allele-specific copy number profiles mainly
in 10 regions. Therefore, we selected the 10 regions for the downstream subclone detection. Cells
with no reads detected in more than five out of the ten regions were filtered out. With the two
processed matrices as the input, Clonalscope was run to detect the subclones based on both
coverage changes and allelic ratios using the default parameters. The final clusters were requested
to include > 50 cells. The subclones detected from Clonalscope were compared to the supervised
clustering used in the previous study, which requires a known number of subclones and their
corresponding copy number profiles from scDNA-seq data. The two methods were shown parallelly
for easier comparison.
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WES data processing
The bam file of the WES data from SCC P6 was retrieved from GSE144240. On the bam files for
matched tumor and normal samples, we first quantified the reads in each window with a 100,000
bp size by running the “intersect” command in the bedtools [141]. Then by normalizing with the
matched normal WES data, we segmented the genome into regions with the same copy number
states using the HMM segmentation function in Clonalscope. Since the dataset was originally
aligned to hg19, we used the LiftOver tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver) to convert
the segments to GRCh38 to be compatible with the matched ST dataset.

Spatial transcriptomics (ST) data analysis
Clonalscope was run to detect subclones without considering spatial loci in ST datasets. The
estimated clonal identity of each spot can then be visualized spatially, enabling the integration of
the two types of signals. Seurat was used to align each spot to the corresponding loci in the H&E
image.
For the SCC P6 sample, the copy number profiles of the identified malignant spots in the two
replicates were compared to each other by computing the correlation. The mean segmentation
plots for the two replicates were generated by connecting every breakpoint along with the genomic
coordinates. The spatial distributions of the malignant spots were also shown.
On the IDC sample with 2 sections, to trace subclones from one ST dataset to another ST dataset,
we used the subclones detected on the first slide section (section 2) as the prior clusters for
Clonalscope’s subclone detection on another section (section 1). The prior clusters can be easily
provided to Clonalscope, and the direct information from bulk DNA-seq data is ignored in this mode.
For subclone tracing, Clonalscope first assigns each cell in the second section to the prior clusters
based on the minimum distance. Then the regular nested Chinese Restaurant Process can be run
to add new clusters or remove existing clusters. On the IDC sample with three subclones detected
(Fig. 5), we assessed the difference in the mean copy number profiles of the three clones.
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Differential gene expression analysis on the three clones was performed using the “FindMarkers”
function in Seurat [140]. Each of the three subclones was compared against the other two
subclones in the comparison.
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Figures

Figure 3.1: Overview of subclone detection with Clonalscope.
Step 1. The algorithm starts from a segmentation of the genome based on matched WGS or WES
data. Step 2. For each segment, Clonalscope computes the coverage change of each cell in
scRNA-seq data by normalizing to a set of normal cells. This step reduces the raw gene-by-cell
matrix for the UMI counts to the segment-by-cell matrix. Step 3. Clonalscope implements a nested
Chinese Restaurant Process to iteratively assign each cell into one of the existing clusters, add or
select copy number states for each segment (1st Chinese Restaurant Process), and seeds new
clusters (2nd Chinese Restaurant Process) (Methods). For ST data, the setting is similar but “cell”
is substituted with “spot”. Optionally, Clonalscope can also operate on both coverages and allelic
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ratios for subclone detection on scATAC-seq data. In addition to the segment-by-cell matrix for fold
changes, Alleloscope can be used to retrieve the segment-by-cell matrix for allelic ratios.
Clonalscope then detects subclones based on both types of information.
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Figure 3.2: Subclone detection and malignant cell labeling for scRNA-seq data validated by
matched scDNA-seq data.
a. Correlations between the copy number profiles from matched DNA-seq data and those from
different segmentation methods on four gastrointestinal tumor samples. b. Malignant cell labeling
from Clonalscope (left), CopyKAT (middle), and Hierarchical clustering with 2 major groups (right)
on the P6198 scRNA-seq data. T and N represent the estimated tumor and normal cells
respectively. G1 and G2 stand for the first and second major groups from hierarchical clustering. c.
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Mapping the detected subclones from Clonalscope (top), CopyKAT (middle), and inferCNV(bottom)
in scRNA-seq data (right) to those observed in the matched scDNA-seq data (left) for the P5931
malignant cells (Methods).
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Figure 3.3: Subclone detection based on coverage and allelic ratio in the scATAC-seq data
from the SNU601 gastric cancer cell line.
a. Segmentation plot of the pseudo-bulk scDNA-seq dataset from the SNU601 sample. b. The six
major subclones detected on the matched scDNA-seq data from hierarchical clustering with ten
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regions shown in plot c. The result of subclone detection from Clonalscope on the scATAC dataset.
The clusters from Clonalscope (C) and supervised classification (S) are shown parallelly in the left.
In the color legend, M and m represent the major haplotype and minor haplotype, respectively.
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Figure 3.4: Malignant spot labeling and subclone tracing on spatial transcriptomics (ST)
data.
a. Segmentation plot of the whole-exome sequencing (WES) data from the squamous cell
carcinoma (SCC) Patient 6 (P6) sample. b. Malignant cell labeling by Clonalscope on the ST
datasets from SCC P6 replicate 1 (left) and replicate 2 (right). c. The H&E image of the SCC P6
replicate 1 sample with pathology annotation. d. Normalized genome-wide copy number profiles
between the identified malignant cells in the two replicates. e. The scatter plot of the mean read
counts for each region across the identified malignant cells for SCC P6 replicate 1 against those
for replicate 2. f. Illustration of the scheme for subclone detection using Clonalscope. Clonalscope
can leverage the prior subclones from the first dataset to detect subclones in another related
dataset. g. Subclones detected from Clonalscope in the ST datasets from section 2 (left) and
section 1 (right) of an invasive ductal carcinoma (IDC) sample. h. The H&E image of the IDC section
1 sample with pathology annotation.
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Figure 3.5: Subclone detection and differential gene analysis on an invasive ductal
carcinoma sample.
a. Subclones detected from Clonalscope on the ST dataset from an invasive ductal carcinoma
sample. b. The mean copy number profiles across the cells assigned to the three spatially
segregated subclones (bottom), and the density plots of four regions with significant differences in
the copy number states for at least one of the three subclones (top). c. and d. show the top 6 highly
expressed genes for cluster 3 and cluster 4. The color scale indicates the numbers of UMIs for
each gene.
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Supplementary Figures
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Supplementary Figure 3.1: Comparison of the mean coverage changes using segments from
different methods to those observed in matched (pseudo)bulk DNA-seq data on four
gastrointestinal samples.
The mean coverage changes in scRNA-seq data using segments from inferCNV (sky-blue),
CopyKAT (purple), and bulk DNA-seq data (red) were compared against the mean coverage
changes in DNA-seq data (black). Four segmentation plots are aligned for each sample. The four
samples are P5847 (top left), P5931 (top right), P8823 (bottom left), and P6198 (bottom right).
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Supplementary Figure 3.2: Malignant cell labeling result from CopyKAT for the P6198
scRNA-seq data.
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Supplementary Figure 3.3: Hierarchical clustering result on the values of fold changes for
each cell and each segment for the P6198 scRNA-seq data.
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Supplementary Figure 3.4: UMAP plots for the epithelial cells in matched tumor and normal
scRNA-seq data from the P5931 sample.
The matched tumor and normal scRNA-seq data were analyzed together for dimensionality
reduction, clustering and cell-type annotation.
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Supplementary Figure 3.5: Proportions of the subclones detected from Clonalscope,
CopyKAT, and inferCNV compared to those observed in the matched scDNA-seq data for
the P5931 tumor sample.
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Supplementary Figure 3.6: Hierarchical clustering result on the values of fold changes in
ten marker regions for each cell in the SNU601 scATAC-seq data.
The supervised classification is shown in the left. In the color legend, M and m represent the major
haplotype and minor haplotype, respectively.
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Supplementary Figure 3.7: Heatmap showing frequencies for each combination of clusters
from Clonalscope estimation and supervised classification.
The color scale represents the standardized values for each column.
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Supplementary Figure 3.8: Consensus plot of the subclone detection result from
Clonalscope on the SNU601 scATAC-seq dataset.
The clusters from Clonalscope and supervised classification are shown parallelly in the left. In the
color legend, M and m represent the major haplotype and minor haplotype, respectively.
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Supplementary Figure 3.9: UMAP projection of genome-wide scATAC-seq peak profile on
2,753 cells colored by the clusters from supervised classification (left) and Clonalscope
estimation (right).
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Supplementary Figure 3.10: Supplementary Figure 3.10: Heatmaps showing the subclone
detection and malignant cell labeling results from Clonalscope on the ST datasets from two
replicates of the SCC P6 sample.
The heatmaps for replicate 1 and replicate 2 are shown in the top and bottom respectively. In the
legend, ‘Annot’ represents the annotation of tumor (T) and normal (N) cells.
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Supplementary Figure 3.11: Heatmap showing the subclone detection result from
Clonalscope on the ST datasets from an IDC sample.
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Supplementary Tables
Supplementary Table 3.1: Summaries of the scRNA-seq and scATAC-seq datasets.

Sample

Cancer
type

Source

Paired
normal

Type

Mean reads
per cell

Cell
number

Ref

P5847

Gastric

Primary
tissue

No

scRNA-seq

16,184

7,387

-

P5931

Gastric

Primary
tissue

Yes

scRNA-seq

19,129

5,861

[136]

P6198

Colorectal

Liver
meta

No

scRNA-seq

51,399

7,190

[137]

P8823

Colorectal

Primary
tissue

No

scRNA-seq

26,366

26,523

-

Sample

Cancer
type

Source

Paired
normal

Type

Median
frags per cell

Cell
number

Ref

SNU601

Gastric

Ascites
meta

No

scATAC-seq

69,455

3,614

[76]

Ref

Supplementary Table 3.2: Summaries of the DNA-seq datasets.

Sample

Cancer
type

Source

Type of
DNA-seq

Coverage
per cell

Cell
number

P5847

Gastric

Primary tissue

scDNA-seq

422,134

715

P5931

Gastric

Primary tissue

scDNA-seq

730,932

796

-

P6198

Colorectal

Liver meta

Pseudo bulk

-

-

[99]

P8823

Colorectal

Primary tissue

WGS

-

-

-

SNU601

Gastric

Ascites meta

scDNA-seq

565,648

1,531

[93]
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4. CHAPTER 4 CONCLUSION AND FUTURE DIRECTIONS

Conclusion
In this dissertation, I presented two computational methods we developed— Alleloscope (Chapter
2) and Clonalscope (Chapter 3) for (allele-specific) copy number and subclone detection in singlecell and ST tumor sequencing data, enabling integrative analysis between different omics for the
detected subclones. Alleloscope is a method for allele-specific copy number detection that can be
applied to scDNA-seq and scATAC-seq data with sample-matched bulk DNA-seq data. On
gastrointestinal and breast cancer samples, Alleloscope found pervasive occurrence of highly
complex multi-allelic CNAs, which were missed in previous studies without allele-specific CNA
analysis at the single-cell level. The results were for the first time, validated using WGS haplotypes
provided by the matched linked-read sequencing data. By detecting subclones in scATAC-seq data,
Alleloscope also enables multi-omics analysis of clonal evolution and altered chromatin
accessibility.
To reliably detect subclones based on copy number profiles, we also developed Clonalscope, a
subclone detection method modeling the intratumor evolutionary process. Clonalscope can be
applied to single-cell and spatial tumor sequencing data. On gastrointestinal tumor, BCC and IDC
samples, Clonalscope was able to accurately detect subclones, label malignant cells/spots, and
trace subclones between related datasets. On an ST dataset of an IDC sample, Clonalscope
discovered genetically distinct subclones which were segregated spatially and expressed genes
associated with outcomes of therapies. Through the development of the two computational
methods, we hope to facilitate more comprehensive multi-omics analysis for single-cell and ST
tumor sequencing data in the future.
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Future directions

Reliably identify subclones and profile CNAs for more tumor types
Alleloscope enables allele-specific CNA detection for scDNA-seq and scATAC-seq data. By allelespecific CNA analysis, we discovered pervasiveness of the haplotype-level diversity in multiple
samples from gastrointestinal and breast tumors which are either primary or metastatic tumors.
The haplotype-divergent CNA configurations enable us to reliably identify subclones that were not
differentiable with earlier coverage-only analysis. In the future, it will be interesting to apply
Alleloscope to datasets of more tumor types, which will help to characterize the general landscape
of tumor heterogeneity across different tumors. Reliable detection of subclones and allele-specific
CNA events will also facilitate reconstruction of tumor evolution. Additionally, Alleloscope is also
the first method to reliably detect CNAs in scATAC-seq data. By profiling both coverage change
and allelic imbalance, false-positive CNA signals can be decreased compared to the coveragealone methods. As researchers are more interested in epigenetics with more tumor scATAC-seq
datasets generated nowadays, Alleloscope brings the opportunity to integrate genome and
epigenome for different tumor types on the scATAC-seq datasets.

Functional characterization of allele-specific CNAs
Analysis of allele-specific CNAs by Alleloscope requires detection of both coverage changes and
allelic ratios from heterozygous SNPs. Most current scRNA-seq only sequence either the 3′ or 5′
end of the messenger RNA transcripts, limiting the number of heterozygous SNPs observed in the
data. So far, only two studies have tried to detect multiallelic CNAs for the same regions [76, 82].
Yet functional effects of these multiallelic CNAs are still unknown. With the latest developments in
single-cell long-read sequencing [110-112] and single-cell multimodal sequencing [113],
Alleloscope can potentially be applied to the datasets generated from these new single-cell
sequencing technologies to identify allele-specific CNAs. This will enable not only the study of the
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effect of multiallelic CNAs on gene expression, but also integrative analysis of multiple modalities
for tumor subclones.

Identify key subclones that are resistant to therapies and characterize the landscape of
tumors across tissue sections
In Chapter 3, I demonstrated Clonalscope’s ability in tracing subclones between associated
datasets from two sections of an IDC sample. This characteristic greatly broadens Clonalscope’s
applications in cancer biology such as tracing subclones before and after treatments, or matching
subclones in different sites of the same tumors. Intratumor subclones can contribute to drug
resistance and relapse [4, 5]. On scRNA-seq datasets from tumor samples before and after
therapies, if a subclone observed after therapies is also present in the samples before therapies,
this subclone is highly likely to be the therapy-resistant subclone seeded in the tumor sample. By
characterizing the genetic and transcriptomic profiles, we may infer mechanisms that potentially
play key roles in drug or therapy resistance. On time-series spatial transcriptomics datasets, we
can even study the microenvironment of these drug-resistant subclones in addition to looking at
the genetic and transcriptomic profiles of these subclones. On the other hand, if subclones in
separate tissue sections within the same tumor can be linked with each other, more comprehensive
spatial distribution of the subclones can be studied. This characteristic of Clonalscope helps to
alleviate the size limitations of individual tissue slides. Applications of Clonalscope on single-cell or
ST sequencing datasets from different types of tumors will facilitate identifying key subclones and
creating a more comprehensive picture of tumors.

Study interactions between stromal cells and malignant cells focusing on the clusters with
a mixture of malignant and stromal cells
On ST datasets, Clonalscope not only identified genetically different subclones, but also delineated
the tumor’s invasive front with a mixture of malignant and stromal cells. In Chapter 3, the main
focus was the detection of subclones with distinct copy number profiles although the regions with
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a mixture of malignant and stromal cells were also separated into new clusters. The spots were
considered as the tumor’s invasive front by Clonalscope and can be further focused to study the
interactions between stromal cells and malignant cells of different subclonal origins. By applying
existing computational methods such as RCTD [142] to deconvolve signals from each cell type in
the invasive front, associations of gene expression between individual cell types and different
subclones can be investigated within specific intratumor microenvironment. To study the
interactions between malignant and stromal cells, it will also be helpful to estimate the purity of
malignant cells for each spot in the ST data. If the copy number profile of malignant cells can be
retrieved from matched bulk DNA-seq or the spots known to be mainly malignant cells, we can
incorporate a computational method into Clonalscope to estimate the proportion of malignant cells
for each spot based on the copy number states of all segments. With these characteristics,
Clonalscope will be more versatile and be able to depict a more comprehensive picture of
intratumor microenvironment.

Prioritize genes/peaks in tumor subclones for follow-up
In my thesis work, I demonstrated that Allelosocope and Clonalscope can detect (allele-specific)
CNAs and subclones in different types of single-cell and ST tumor sequencing data, which enables
multi-omic integration between different modalities at the subclonal level. By applying Alleloscope,
differentially accessible peaks in genetically distinct subclones can be detected with adjustment of
the underlying copy numbers. These peaks and nearby genes can be prioritized for follow-up. In
the dissertation, we demonstrated Alleloscope’s ability of multi-omic integration on a gastric cancer
cell line. It will be extremely interesting and helpful if this integration can also be performed on
tumor samples from patients if suitable datasets are available. Similarly, differentially expressed
genes in spatially segregated subclones detected by Clonalscope can also be followed up for
functional characterization. Our current applications of Clonalscope were mostly on public datasets,
so the results were not easy to be experimentally validated. We hope to apply Clonalscope on more
scRNA-seq and ST datasets to identify subclones with high adaptability due to specific
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transcriptomic profiles, which can be validated if possible. Identifying important genes/peaks that
increase the adaptability of specific subclones will facilitate cancer prognosis and treatment.

Integrate different types of DNA mutations in subclone detection
My dissertation focused on one type of DNA mutation— CNAs in subclone detection. So far, CNAs
are the DNA mutations most commonly used to build subclones and reconstruct tumor evolution
since their signals are more apparently captured in current single-cell or ST sequencing data.
However, there are other types of DNA mutations such as SNVs and indels that cannot be easily
detected in most single-cell sequencing data due to the limitation of technologies. For example,
most scRNA-seq data only contain sequences from the 3’ or 5’ ends of the transcripts, which limits
our discovery of SNVs and other DNA mutations. Recently, the advancement of long-read
sequencing techniques can sequence full transcripts, which enables us to study potential mutations
such as SNVs in coding regions. The identified SNVs and other DNA mutations can also be used
to identify subclones and reconstruct tumor lineage history combining with CNAs. As more
technologies are developed and improved in the future, different types of mutations can be profiled
to provide a more comprehensive picture through the integration of multiple modalities.
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